

Metadata of the article that will be visualized in OnlineFirst

Please note: Images will appear in color online but will be printed in black and white.

1	Article Title	Seaweed extracts as antimicrobial agents in aquaculture	
2	Article Sub- Title		
3	Article Copyright - Year	Springer Science+Business Media Dordrecht 2014 (This will be the copyright line in the final PDF)	
4	Journal Name	Journal of Applied Phycology	
5		Family Name	Vatsos
6		Particle	
7		Given Name	Ioannis N
8	Corresponding	Suffix	
9	Author	Organization	University of Nordland
10		Division	Faculty of Biosciences and Aquaculture
11		Address	Post Office Box 1490, Bodø 8049, Norway
12		e-mail	inv@uin.no
13		Family Name	Rebours
14		Particle	
15		Given Name	Celine
16		Suffix	
17	Author	Organization	Bioforsk, Norwegian Institute for Agricultural and Environmental Research
18		Division	
19		Address	Frederik A. Dahlsvei 20, Ås 1430, Norway
20		e-mail	celine.rebours@bioforsk.no
21		Received	21 July 2014
22	Schedule	Revised	10 December 2014
23		Accepted	11 December 2014
24	Abstract	In the last 20 years, there has been an increasing interest in using various seaweed extracts as prophylactic and/or therapeutic agents in aquaculture. Up until now, most studies on the direct antimicrobial effect of seaweeds have taken place in various parts of Asia, particularly in India. All groups of seaweeds exhibit significant antimicrobial properties against many infectious agents of fish and shrimp, but the genera that appear to exhibit a broader range of antibacterial properties are <i>Asparagopsis</i> spp. (red seaweed) and <i>Sargassum</i> spp. (brown seaweed). The activity can	

be affected by many factors and the method of extraction is one of the most important ones, as the extracts that are produced using organic solvents appear more efficient. In fish, almost all published information on bacterial pathogens comes from in vitro screenings, where extracts of different seaweed species were tested against many bacterial species. On the other hand, in shrimp, the studies have been focusing on the antimicrobial effects of seaweed extracts mainly against many *Vibrio* species. Regarding the viral pathogens, in fish, there is only one published study on fish viruses (IHNV and IPNV), while in shrimp there are many studies on WSSV. There are only two published studies on fish parasites (*Ichthyophonus hoferi* and *Neobenedenia* spp.) and no studies on pathogenic fish and shrimp fungi. Interestingly, there are no published studies on salmon and carps, the main fish species that are extensively farmed. When the antimicrobial properties were studied in vivo, the seaweed extracts were either incorporated directly in the feeds (dry or live) or added directly into the water in which the fish and shrimp were reared. In the last case, the water-soluble antimicrobial seaweed substances affected the communication between the bacterial pathogens, rather than their growth. The development of parasites was also affected. In addition, one study indicated that short-term immersion of shrimp in seaweed extracts appeared to have a therapeutic effect against *Vibrio parahaemolyticus*. On the other hand, incorporation of the extracts into the feeds appeared to be an effective delivery method for the prevention and treatment of different infectious diseases. Up until now, there are no complete studies on the pharmacodynamics and pharmacokinetics of seaweed extracts in fish or shrimp. However, the findings indicate that they can reduce the bacterial load within the tissues. Another issue that has not been examined yet is the applicability of using these extracts on a commercial scale. Currently, the increased extraction cost inhibits the extensive use of these extracts. Other methodologies, such the production of synthetic analogues with similar properties, may decrease the production cost. Based on the published studies, seaweed extracts exhibit promising antimicrobial properties, but further research is needed before the complete potential of seaweed extracts is assessed.

25	Keywords separated by ' - '	Seaweed - Antimicrobial - Fish - Shrimp - Aquaculture
26	Foot note information	

Seaweed extracts as antimicrobial agents in aquaculture

Ioannis N Vatsos · Celine Rebours

Received: 21 July 2014 / Revised and accepted: 10 December 2014
© Springer Science+Business Media Dordrecht 2014

Abstract In the last 20 years, there has been an increasing interest in using various seaweed extracts as prophylactic and/or therapeutic agents in aquaculture. Up until now, most studies on the direct antimicrobial effect of seaweeds have taken place in various parts of Asia, particularly in India. All groups of seaweeds exhibit significant antimicrobial properties against many infectious agents of fish and shrimp, but the genera that appear to exhibit a broader range of antibacterial properties are *Asparagopsis* spp. (red seaweed) and *Sargassum* spp. (brown seaweed). The activity can be affected by many factors and the method of extraction is one of the most important ones, as the extracts that are produced using organic solvents appear more efficient. In fish, almost all published information on bacterial pathogens comes from in vitro screenings, where extracts of different seaweed species were tested against many bacterial species. On the other hand, in shrimp, the studies have been focusing on the antimicrobial effects of seaweed extracts mainly against many *Vibrio* species. Regarding the viral pathogens, in fish, there is only one published study on fish viruses (IHNV and IPNV), while in shrimp there are many studies on WSSV. There are only two published studies on fish parasites (*Ichthyophonus hoferi* and *Neobenedenia* spp.) and no studies on pathogenic fish and shrimp fungi. Interestingly, there are no published studies on salmonids and carps, the main fish species that are extensively farmed. When the antimicrobial properties were studied in vivo, the seaweed extracts were either incorporated

directly in the feeds (dry or live) or added directly into the water in which the fish and shrimp were reared. In the last case, the water-soluble antimicrobial seaweed substances affected the communication between the bacterial pathogens, rather than their growth. The development of parasites was also affected. In addition, one study indicated that short-term immersion of shrimp in seaweed extracts appeared to have a therapeutic effect against *Vibrio parahaemolyticus*. On the other hand, incorporation of the extracts into the feeds appeared to be an effective delivery method for the prevention and treatment of different infectious diseases. Up until now, there are no complete studies on the pharmacodynamics and pharmacokinetics of seaweed extracts in fish or shrimp. However, the findings indicate that they can reduce the bacterial load within the tissues. Another issue that has not been examined yet is the applicability of using these extracts on a commercial scale. Currently, the increased extraction cost inhibits the extensive use of these extracts. Other methodologies, such the production of synthetic analogues with similar properties, may decrease the production cost. Based on the published studies, seaweed extracts exhibit promising antimicrobial properties, but further research is needed before the complete potential of seaweed extracts is assessed.

Keywords Seaweed · Antimicrobial · Fish · Shrimp · Aquaculture

Introduction

With an average annual growth rate of 8.9 % since 1970, aquaculture is considered to be the fastest growing food-producing sector in the world and accounts for about 36 % of the global fish supply and almost 60 % of the global shrimp supply (FAO 2014). In terms of quantity, farming of cyprinids dominates the aquaculture production, with 25.4 million T,

I. N. Vatsos (✉)
Faculty of Biosciences and Aquaculture, University of Nordland,
Post Office Box 1490, 8049 Bodø, Norway
e-mail: inv@uin.no

C. Rebours
Bioforsk, Norwegian Institute for Agricultural and Environmental
Research, Frederik A. Dahlsvei 20, 1430 Ås, Norway
e-mail: celine.rebours@bioforsk.no

71 while the production of salmonids and crustaceans (shrimp
72 and prawns) contributes with 3.2 and 4.3 million T, respec-
73 tively (FAO 2014). Diseases, either infectious or non-infec-
74 tious, are important limiting factors that affect the production
75 volume and consequently the production cost. In 2006, for
76 instance, for a global production of 1.6 million T of salmon,
77 the cost for sea lice treatments was estimated at 305 million €
78 (Costello 2009). It has been estimated that in Norway, the top
79 salmonid producer in the world, the cost of sea lice control is
80 about 0.19 €kg⁻¹ of salmon (Costello 2009). Furthermore, it
81 was estimated that in 2010, over 77 million USD were spent in
82 Norway on fish diseases management, including the imple-
83 mentation of legislation and support to surveillance and con-
84 trol programmes (The Fish Site 2010).

85 The development of many vaccines, mainly against fish
86 pathogens, and the use of various antimicrobial agents have
87 reduced the impact of many diseases. However, there is cur-
88 rently an increasing demand for more environment-friendly
89 disease control schemes and many researchers have examined
90 alternative approaches. Among these approaches, the use of
91 various natural products that derive from different living or-
92 ganisms, such as plants (e.g. essential oils), animals (e.g.
93 chitozan) and seaweeds has received a lot of attention
94 (Romero et al. 2012).

95 Seaweeds, also known as macroalgae, are photosynthetic
96 multicellular aquatic organisms that can be found in almost
97 every aquatic environment, in all geographical areas. Humans
98 had realized their important value as early as 14,000 years ago
99 (Dillehay et al. 2008). The first reports of seaweeds growing
100 on ropes used for fish farming came from Japan, about
101 400 years ago (Buchholz et al. 2012). A more systematic
102 culture started in the 1950s, in order to meet the increasing
103 demand for seaweeds as food and mostly as sources of poly-
104 mers. In 2012, over 21 million tons of seaweeds were pro-
105 duced, over 96 % of which were cultured in Asia (FAO 2014).

106 Many studies on different seaweed species have confirmed
107 their nutritional value. In particular, seaweeds are low in
108 calories, have high content of dietary fibres, are a good source
109 of polyunsaturated fatty acids DHA and EPA, and may con-
110 tain proteins up to 44 % dry matter with an amino acid profile
111 of interest (Holdt and Kraan 2011). The red and the green
112 seaweeds are generally rich in carbohydrates, whereas the
113 brown seaweeds are generally richer in soluble fibre and
114 iodine (Gupta and Abu-Ghannam 2011a). In some cases,
115 some essential amino acids might be limiting, as for example
116 tryptophan, while the concentration of other amino acids, like
117 taurine, can be high particularly in red algae (Dawczynski
118 et al. 2007). In addition to their nutritional value, seaweeds
119 exhibit interesting pharmacological properties, such as anti-
120 oxidant, anti-inflammatory, antimicrobial and even anticancer
121 properties (El Gamal 2010; Gupta and Abu-Ghannam 2011a;
122 Gupta and Abu-Ghannam 2011b; Holdt and Kraan 2011;
123 Mohamed et al. 2012). The active compounds include

polysaccharides (e.g. fucoidan), various phytochemicals (e.g. 124
phlorotannins), carotenoids, minerals, peptides and lipids 125
(Gupta and Abu-Ghannam 2011b; Holdt and Kraan 2011). It 126
is worth mentioning that some of these compounds, as for 127
example phlorotannins, are not found in terrestrial plants. 128

129 The present review focuses on published studies on the
130 direct antimicrobial properties of seaweeds and their extracts
131 against various pathogens of farmed fish and shrimp. Many of
132 these extracts also exhibit significant immunostimulatory
133 (Caipang et al. 2011) and antioxidant properties (Kang et al.
134 2013; Wijesinghe et al. 2014), which can enhance the resis-
135 tance and immune response against many infectious agents,
136 but these will not be discussed in the present review.

Control of infectious diseases in aquaculture 137

138 In contrast to terrestrial farmed animals, most of the fish
139 species that are farmed today have been recently domesticated
140 from wild populations and thus they are still not well adapted
141 to the conditions that exist in farms (Kibenge et al. 2012).
142 Many of these conditions, such as crowding, regularly han-
143 dling, improper water quality parameters and the use of arti-
144 ficial commercial feeds, can cause various degrees of stress to
145 fish, which in turn can make them more vulnerable to all
146 infectious diseases (Huntingford et al. 2006). As a rule, the
147 most common infectious diseases that are observed in farmed
148 aquatic animals are those associated with bacterial pathogens
149 (about 50 %), followed by the viral, the parasitic and finally
150 the fungal diseases (McLoughlin 2006). Differences, depend-
151 ing on the species and country, may exist. For instance, in
152 farmed salmonids, bacterial diseases are not considered a
153 major problem compared to the losses caused by viral agents,
154 but in marine fish species bacterial diseases are far more
155 important in terms of financial loss and frequency (Johansen
156 et al. 2011).

157 The control of the infectious diseases that affect the farmed
158 aquatic animals relies on the use of effective prophylactic as
159 well as therapeutic measures. Numerous studies have demon-
160 strated that the extensive use of various chemotherapeutants
161 used for the treatment of the parasitic, bacterial and fungal
162 diseases in aquaculture have serious impacts on the environ-
163 ment and increase the health risks for both humans and ani-
164 mals (Burridge et al. 2010). It is well established for instance
165 that the extensive use of various chemicals induces a strong
166 selective pressure on the pathogens, resulting in the appear-
167 ance of multi-resistant strains. Subsequently, through the hor-
168 izontal exchange of genetic material that occurs between
169 bacterial species, this resistance, which is an important viru-
170 lence factor for many pathogens, is transferred to other path-
171 ogens. Furthermore, the resistance to the antimicrobial agents
172 that is developed in animal bacterial pathogens can be also
173 transferred to human pathogens (Martinez 2009).

174 In aquaculture, the main routes of administration of the
 175 various chemotherapeutants are either via medicated feeds or
 176 by immersion. Both of these methods can have a direct impact
 177 on a wide range of bacterial species that live in the aquatic
 178 environment. In both cases, it is very difficult to control the
 179 leaching of the active substances to the immediate environ-
 180 ment (Heuer et al. 2009) and thus residues of many antimi-
 181 crobials are often found in the sediment under the fish and
 182 shellfish farms (Petersen et al. 2002; Romero et al. 2012).
 183 Miranda and Zemelman (2002) studied the presence of
 184 oxytetracycline-resistant bacteria in the environment of Chil-
 185 ean salmon farms and found that the number of
 186 oxytetracycline-resistant bacteria was significantly increased
 187 in the effluent water. The presence of these resistant bacteria
 188 was associated with previous treatments that took place in the
 189 farms. These findings are of great significance as many
 190 in vitro studies have already demonstrated the transferability
 191 of antibiotic resistance genes between fish or shrimp and
 192 human pathogens (Heuer et al. 2009). Moreover, the use of
 193 the various chemotherapeutants, including the antibiotics, has
 194 negative effects on many functions of the fish immune system.
 195 Romero et al. (2012) in their review on the use of antibiotics in
 196 aquaculture noted that treatment with oxytetracycline and
 197 oxolinic acid could induce significant immunosuppression in
 198 many fish species, while a less pronounced effect was ob-
 199 served after a treatment with florfenicol. All these findings
 200 stress therefore the urgency to minimize the use of any
 201 chemotherapeutant in aquaculture and indeed many coun-
 202 tries have already developed strict legislations concerning
 203 their uses.

204 This necessity to reduce the use of chemicals is an impor-
 205 tant issue not only in aquaculture but in the whole animal
 206 farming industry. According to a report by World Human
 207 Organization (WHO 2011), the implementation of effective
 208 biosecurity measures, the development of new vaccines, the
 209 use of prebiotics and probiotics, and good hygiene and man-
 210 agement practices are quite important for the control of many
 211 infectious diseases in both terrestrial and aquatic animal farm-
 212 ing and can lead to a significant reduction in the use of
 213 antibiotics in animal farming. Furthermore, new legislations
 214 that would regulate and monitor the use of antibiotics should
 215 be implemented, while the use of antibiotics as growth pro-
 216 moters should be banned worldwide. Only qualified people,
 217 preferably veterinarians, should be responsible for monitoring
 218 the use of all chemicals used in animal farming. Experience
 219 from the terrestrial animal husbandry indicates that indeed
 220 strict legislations that require reduced use of antibiotics do
 221 not necessary result in increased costs to the farmers, as for
 222 example a survey in swine farms in Denmark has demonstrat-
 223 ed (Aarestrup et al. 2010).

224 There is however a significant variation between countries
 225 concerning the use of chemotherapeutants, which may reflect
 226 the diverse degree of awareness of each society for

environmental issues. This results in heterogeneity between 227
 the legislations in effect, in aquaculture producing countries. 228
 For example, Burrige et al., (2010) reported that the amount 229
 of antibiotics used in salmon farming between 2007 and 2008 230
 in Chile and Norway, the two main salmon producing coun- 231
 tries, was a few hundred metric tons in Chile and less than a 232
 metric ton in Norway. Furthermore, in many countries, fish 233
 and shellfish farmers use increased amounts of various anti- 234
 microbial substances, even on a daily basis, as a preventive 235
 measure (Heuer et al. 2009). 236

237 As societies become more aware of the negative effects of 237
 the various treatments that are employed today in the control 238
 of the infectious diseases in aquaculture, various alternative 239
 approaches have been suggested. These include the use of 240
 probiotics to enhance the immune response of fish and shell- 241
 fish, the use of bacteriophages against bacterial pathogens and 242
 the use of various natural products, such as essential oils, as 243
 antimicrobial agents (Romero et al. 2012). Among them, 244
 seaweeds have also been examined as potential sources of 245
 antimicrobial substances (Gupta and Abu-Ghannam 2011b). 246

247 **Seaweeds versus fish and shrimp pathogens**

248 The dietary value of seaweeds, as potential substitutes for 248
 fishmeal, or as binding agents, has been extensively studied 249
 and the findings indicate that seaweed-based diets can be used 250
 for the farming of many aquatic organisms, such as fish, 251
 shrimp, sea urchins and abalones (Bindu and Sobha 2004; 252
 Henry 2012). Seaweeds have relatively simple cultivation 253
 methods and can grow fast. It is also possible to control the 254
 production of some of their bioactive extracts through the 255
 manipulation of the cultivation conditions (Plaza et al. 256
 2008). Recent studies have focused on culture systems inte- 257
 grating seaweed with fish or shrimp production. In these 258
 Integrated Multitrophic Aquaculture Systems (IMTA), the 259
 seaweeds play an important role first as biofilters and secondly 260
 as a source of biomass (Barrington et al. 2009). Seaweeds 261
 receive the nutrient-rich waste water from the fish or shellfish 262
 and use it for their growth. In this way, they can reduce the 263
 negative environmental impacts of fish farming through the 264
 removal of the waste materials (mainly N and P) that are 265
 released from the animals in the farms. The produced seaweed 266
 biomass adds market value to the production system, as they 267
 can later be used in food, or pharmaceutical industry (Al- 268
 Hafedh et al. 2012). 269

270 The antimicrobial properties of seaweed extracts against 270
 many human and terrestrial animal pathogens are known since 271
 the end of the nineteenth century (Genovese et al. 2012). 272
 These antimicrobial properties can be affected by many fac- 273
 tors, such as the habitats, the cultivation method, the growth 274
 stage of seaweeds, the season and the method used for the 275
 extraction of the bioactive components (Karthikaidevi et al. 276

277 2009; Govindasamy et al. 2011). For example, Osman et al.
 278 (2012), after screening many seaweed species against *Bacillus*
 279 *subtilis*, *Staphylococcus aureus*, *Streptococcus* spp. and
 280 *Escherichia coli*, found that green seaweeds and particularly
 281 *Ulva fasciata*, tended to exhibit higher antimicrobial activity.
 282 This was more pronounced when the green seaweeds were
 283 collected in winter. On the other hand, Salvador et al. 2007
 284 found that red seaweeds exhibited higher antimicrobial prop-
 285 erties against many bacterial species, particularly the sea-
 286 weeds which were collected in autumn. Regarding the method
 287 of extraction, organic solvents generally tend to be more
 288 efficient for the extraction of the active substances than water
 289 (Abu-Ghannam and Rajauria 2013) and fractioned seaweed
 290 extracts appear more effective compared to crude (Radhika
 291 et al. 2014). One important characteristic of seaweeds that
 292 may pose a health risk is that they are prone to absorb heavy
 293 metals from their surrounding environment, especially if they
 294 are located in particularly polluted areas (Bailey et al. 1999).
 295 Furthermore, they may contain substances, such as kainoids,
 296 aplysiatoxins and polycavernosides, which may be toxic to
 297 humans and animals (Smit 2004). For example, significant
 298 ichthyotoxic effects have also been reported by De Lara-Isassi
 299 et al. (2000), who used *Carassius auratus* to assess the toxic-
 300 ity of over 70 seaweed species. They concluded that
 301 Rhodophyta tended to be more toxic, while Chlorophyta
 302 appeared to be the least toxic. In some cases, the seaweed
 303 extracts can be toxic to certain fish and shellfish species, even
 304 at sub-antimicrobial concentrations (Mata et al. 2013).

305 In farmed fish, most studies on the antimicrobial properties
 306 of seaweeds have focused on various bacterial pathogens (14
 307 out of the 17 presented in this review), while fewer studies
 308 exist on viral and parasitic pathogens (1 and 2, respectively,
 309 out of the 17 presented in this review). On the other hand, in
 310 farmed shrimp, the studies focused mainly on various patho-
 311 genic vibrios and the White Spot Syndrome Virus. Interest-
 312 ingly, although there are in vitro studies in the literature that
 313 demonstrate the antifungal activities of many seaweed extracts
 314 against human pathogenic fungi, such as *Aspergillus* spp.
 315 and *Candida albicans* (Plaza et al. 2010; Omar et al.
 316 2012), there are no similar studies on the main pathogenic
 317 fish or shrimp fungi.

318 Despite the numerous studies on the antimicrobial effects
 319 of seaweed extracts against fish and shrimp pathogens, there is
 320 still limited information on the exact mechanism of action for
 321 most of these extracts. The reason is that although an assess-
 322 ment of any antimicrobial substance, as in the case of seaweed
 323 extracts, should include an initial in vitro screening followed
 324 by an in vitro study (Fig. 1), most studies on the antimicrobial
 325 effects of seaweeds in fish and shrimp are either only in vitro
 326 or only in vivo. For example, 8 out of the 39 studies on
 327 seaweeds versus fish and shrimp pathogens discussed in this
 328 review included both in vitro and in vivo assays (Tables 1 and
 329 2). Furthermore, none of the eight studies on the White Spot

Syndrome Virus included any preliminary in vitro study. 330
 Thus, it is not always clear if the observed protective result 331
 is either due to the direct antimicrobial effect, or due to 332
 immunostimulation, or the synergic effect. 333

Bacterial pathogens 334

The main identified active antibacterial compounds found in 335
 seaweeds are as follows: fatty acids, lipophilic and phenolic 336
 compounds, lectins, acetogenins, terpenes, alkaloids, poly- 337
 phenolics, isoprenoid metabolites and hydrogen peroxide 338
 (Mohamed et al. 2012). In general, these substances can (a) 339
 attack the bacterial cell walls and the cell membranes, which 340
 results in an extensive release of intracellular substances or/ 341
 and disruption of the uptake and transportation of substances, 342
 as for example various phlorotannins (Hierholtzer et al. 2014); 343Q4
 (b) reduce the protein and nucleic acid synthesis in the bacte- 344
 rial cells (Cai et al. 2014) and (c) inhibit respiration (Cai et al. 345
 2014). Phlorotannins, as many other terrestrial tannins do, 346
 may also form complexes with some extracellular bacterial 347
 enzymes (Stern et al. 1996), thus reducing their effects. In 348
 most cases, the effects are dose dependent. 349

An area that has received a lot of attention is the effect of 350
 seaweeds and particularly some of their metabolites, on the 351
 quorum sensing mechanism, by which bacterial cells commu- 352
 nicate between each other. This process, which depends on the 353
 population density, involves the production of certain sub- 354
 stances, such as peptides, or lactones, which are then released 355
 into the extracellular environment. When the concentration of 356
 these substances increases beyond a certain level, they are 357
 then detected by specific receptors, located in the bacterial cell 358
 membranes, or cytoplasm. This in turn regulates the expres- 359
 sion of certain genes. Many Gram positive and negative 360
 bacteria use this process to collectively regulate many pro- 361
 cesses, such as bioluminescence, formation of biofilms and 362
 the production of various virulence factors (Manefield et al. 363
 2001; Rutherford and Bassler 2014). Active substances re- 364Q5
 leased from seaweeds, such as furanones, can disrupt this 365
 process, thus affecting the virulence of many pathogenic 366
 bacteria, as for example the virulence of many pathogenic 367
Vibrio species (Defoirdt et al. 2006) (Fig. 2). Because of these 368
 properties and particularly the effect on the biofilm formation, 369
 seaweed extracts have also been studied as antifouling agents 370
 in aquaculture (Jha et al. 2013). It is worth mentioning that an 371
 important advantage of such quorum sensing inhibitors is that 372
 they do not induce strong selection pressure on the bacteria, as 373
 antibiotics do (Dobretsov et al. 2009). 374

Numerous studies have focused on the study of the direct 375
 antibacterial (either bactericidal or bacteriostatic) properties of 376
 seaweed extracts against human bacterial pathogens, such as: 377
B. subtilis, *Enterococcus faecalis*, *Escherichia coli*, 378
Clostridium spp., *Klebsiella pneumoniae*, *Pseudomonas* 379
aeruginosa, *Proteus* spp., *Salmonella typhimurium*, *Shigella* 380

381 *sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*,
 382 *Streptococcus pyogenes* and *Vibrio cholerae* (Vairappan and
 383 Suzuki 2000; Vairappan et al. 2001; Xu et al. 2003; Christobel
 384 et al. 2011; Vijayabaskar and Shiyamala 2011;
 385 Ganeshamurthy et al. 2012; Marudhupandi and Kumar
 386 2013; Saritha et al. 2013). In most cases, only in vitro assays
 387 were used to establish the antibacterial activities, such as dick
 388 diffusion or tube dilution methods.

389 Most of the bacterial species that can cause diseases in fish
 390 and shrimp are quite ubiquitous in the aquatic environment, as
 391 for example many members of the genus *Aeromonas* and the
 392 various pathogenic *Vibrio* species, such as *Vibrio anguillarum*
 393 (also known as *Listonella anguillarum*), *Vibrio alginolyticus*
 394 and *Vibrio harveyi* (Genovese et al. 2012; Cavalo et al. 2013).
 395 Some of these bacteria, such as some pathogenic *Vibrio* spe-
 396 cies, can affect both fish and shrimp and in many cases the

397 manifestation and the progress of the associated diseases are
 398 affected by the presence of various stressful conditions. In
 399 comparison to human bacterial pathogens, fewer studies have
 400 been conducted to identify the antibacterial potential of sea-
 401 weed metabolites against these pathogens.

402 Comparisons between the different studies on the antibac-
 403 terial properties of seaweeds against fish and shrimp are
 404 difficult, as different experimental protocols were used and
 405 particularly in relation to the extraction methods. However, it
 406 is worth noticing that in only 5 out of the 28 studies on fish
 407 and shrimp bacterial pathogens, water was used for the ex-
 408 traction (Table 1). Although none of the three groups of
 409 seaweeds appears to be significantly more effective, as differ-
 410 ent species belonging to all groups are effective against many
 411 bacterial pathogens, *Asparagopsis* spp. (red seaweed) and
 412 *Sargassum* spp. (brown seaweed) appear to exhibit a broader

Fig. 1 A general scheme used in the assessment of antimicrobial activity of seaweed extracts or metabolites. The initial in vitro screening indicates the best candidates for the in vivo studies. This stage can include many assays, depending on the bioactive component and its potential application. The in vivo studies are designed in such a way so that the important information is collected by using the minimum number of animals. Based on all available information, the best method of administration of the tested extract is then proposed




Table 1 Assessment of the antimicrobial properties of seaweed extracts against fish pathogens

	Seaweed genus/species	Extraction method	Fish species	In vitro assays	In vivo assays	Pathogen	Results
t1.1	Bacterial						
t1.2							
t1.3	<i>Asparagopsis armata</i> (a) (red)	Organic solvents	–	Agar diffusion assay	–	<i>Vibrio anguillarum</i> <i>Pseudomonas anguilliseptica</i> <i>Aeromonas salmonicida</i> <i>Aeromonas hydrophila</i> <i>Yersinia ruckeri</i>	In vitro antibacterial activity
t1.4	<i>Laurencia chondrioides</i> (b) (red)	Organic solvents	–	Agar diffusion assay	–	<i>Vibrio anguillarum</i> <i>Pseudomonas anguilliseptica</i> <i>Aeromonas salmonicida</i> <i>Aeromonas hydrophila</i> <i>Yersinia ruckeri</i> <i>Photobacterium damsela</i> sbsp <i>piscicida</i>	In vitro antibacterial activity
t1.5	<i>Mastocarpus stellatus</i> (c) (red) <i>Ceramium rubrum</i> (c) (red) <i>Laminaria digitata</i> (c) (brown)	Organic solvents	–	Bacterial growth inhibition assay	–	<i>Aeromonas salmonicida</i> <i>Vibrio anguillarum</i> <i>Photobacterium damsela</i> subsp. <i>damsela</i> <i>Vibrio alginolyticus</i>	In vitro antibacterial activity
t1.6	<i>Halimeda micronesia</i> (d) (green)	Organic solvents	–	Agar well diffusion assay	–	<i>Yersinia ruckeri</i> <i>Aeromonas hydrophila</i> <i>Vibrio alginoticus</i> <i>V. parahaemolyticus</i> <i>Edwardsiella tarda</i>	In vitro antibacterial activity
t1.7	<i>Asparagopsis taxiformis</i> (e) (red)	Organic solvents	–	Agar diffusion assay	–	<i>Aeromonas salmonicida</i> <i>Photobacterium damsela</i> subsp <i>damsela</i> <i>Photobacterium damsela</i> subsp <i>piscicida</i>	In vitro antibacterial activity
t1.8	<i>Ulva</i> spp. (f) (green)	Organic solvents	–	Agar well diffusion assay	–	<i>Vibrio alginolyticus</i> <i>Vibrio harveyi</i> <i>Vibrio parahaemolyticus</i> <i>Vibrio vulnificus</i>	In vitro antibacterial activity
t1.9	<i>Padina gymnospora</i> (g) (brown) <i>Padina tetrastratica</i> (g) (brown) <i>Sargassum wightii</i> (g) (brown) <i>Turbinaria ornata</i> (g) (brown)	Organic solvents	–	Agar well diffusion assay Disc diffusion assay Minimum inhibitory concentrations	–	<i>Aeromonas hydrophila</i> <i>Edwardsiella tarda</i> <i>Edwardsiella tarda</i> <i>Vibrio alginolyticus</i> <i>Aeromonas hydrophila</i> <i>Renibacterium salmoninarum</i>	In vitro antibacterial activity In vitro antibacterial activity
t1.10	<i>Gracilaria dura</i> (h) (red) <i>Gracilaria gracilis</i> (h) (red) <i>Gracilariopsis longissima</i> (h) (red)	Organic solvents	–	Disc diffusion assay	–	<i>Vibrio ordalii</i> <i>Vibrio salmonicida</i> <i>Vibrio alginolyticus</i> <i>Vibrio vulnificus</i>	In vitro antibacterial activity

Q2 t1.11 Table 1 (continued)

	Seaweed genus/species	Extraction method	Fish species	In vitro assays	In vivo assays	Pathogen	Results
t1.11	<i>Chaetomorpha linum</i> (h) (green) <i>Cladophora rupestris</i> (h) (green) <i>Ulva prolifera</i> (h) (green) <i>Gracilaria corticata</i> (i) (red) <i>Caulerpa racemosa</i> (i) (green) <i>Caulerpa sertularioides</i> (i) (green) <i>Chaetomorpha antennina</i> (i) (green) <i>Padina gymnospora</i> (i) (brown) <i>Sargassum wightii</i> (i) (green) <i>Hypnea musciformis</i> (i) (red) <i>Gracilaria corticata</i> (i) (red) <i>Ulva fasciata</i> (i) (green) <i>Codium tomentosum</i> (i) (green) <i>Sargassum wightii</i> (i) (brown) <i>Dicyota dichotoma</i> (i) (brown) <i>Padina tetrastromatica</i> (i) (brown) <i>Ulva clathrata</i> (k) (green)	Organic solvents	–	Agar well diffusion assay	–	<i>Vibrio parahaemolyticus</i> <i>Aeromonas hydrophila</i>	In vitro antibacterial activity
t1.12	<i>Hypnea musciformis</i> (i) (red) <i>Gracilaria corticata</i> (i) (red) <i>Ulva fasciata</i> (i) (green) <i>Codium tomentosum</i> (i) (green) <i>Sargassum wightii</i> (i) (brown) <i>Dicyota dichotoma</i> (i) (brown) <i>Padina tetrastromatica</i> (i) (brown) <i>Ulva clathrata</i> (k) (green)	Water	–	Disc diffusion assay	–	<i>Vibrio alginolyticus</i> <i>Vibrio fischeri</i> <i>Vibrio harveyi</i>	In vitro antibacterial activity
t1.13	<i>Ulva reticulata</i> (l) (green)	Organic solvents	–	Addition of bacterial suspension in seaweed cultures Minimum inhibitory concentrations Enumeration of bacteria on the surface of seaweed Agar well diffusion method	–	<i>Vibrio anguillarum</i>	Inhibition of bacterial growth in the water
t1.14	<i>Padina tetrastromatica</i> (m) (brown) <i>Stoichospermum marginatum</i> (m) (brown) <i>Ulva fasciata</i> (m) (green) <i>Asparagopsis taxiformis</i> (n) (red)	Organic solvents	–	Agar well diffusion method	–	<i>Aeromonas hydrophila</i> <i>Vibrio alginolyticus</i> <i>Vibrio parahaemolyticus</i>	In vitro antibacterial activity Decrease in number of bacterial colonies
t1.15	<i>Padina tetrastromatica</i> (m) (brown) <i>Stoichospermum marginatum</i> (m) (brown) <i>Ulva fasciata</i> (m) (green) <i>Asparagopsis taxiformis</i> (n) (red)	Organic solvents	–	Agar well diffusion method	–	<i>Aeromonas hydrophila</i>	In vitro antibacterial activity
t1.16	<i>Ulva fasciata</i> (m) (green) <i>Asparagopsis taxiformis</i> (n) (red)	Water	<i>Lates calcarifer</i>	Solid media antagonism assay Broth dilution assay	Immersion challenge followed by	<i>Streptococcus initae</i>	Delay of the growth of the bacterium in the water

1.17 **Table 1** (continued)

	Seaweed genus/species	Extraction method	Fish species	In vitro assays	In vivo assays	Pathogen	Results
t1.17	Viral <i>Polysiphonia morrowii</i> (o) (red)	Organic solvents	-	Cytotoxicity assay Cytopathic effect Plaque reduction assay Cytotoxicity assay.	administration of the extract through the water	Infectious Hematopoietic Necrosis Virus Infectious Pancreatic Necrosis Virus	Not significant reduction in the mortality rate In vitro antiviral activity
t1.18	Parasitic <i>Fucus vesiculosus</i> (p) (brown)	-	<i>Oreochromis niloticus</i>	-	Feeding trial using naturally infected fish	<i>Ichthyophonus hoferi</i>	Reduced mortality
t1.19	<i>Ulva</i> spp. (q) (green) <i>Asparagopsis taxiformis</i> (q) (red)	Water	<i>Lates calcarifer</i>	Immersion treatment of various developmental stages of the parasites	Immersion treatment of infected fish	<i>Neobenedenia</i> spp.	Inhibition of the embryonic development, increase in the time of first and last hatch and reduced hatching success of the parasite

References: (a) Bansemir et al. (2006); (b) Bansemir et al. (2004); (c) Dubber and Harder (2008); (d) Ganeshamurthy et al. (2012); (e) Genovese et al. (2012); (f) Rebecca et al. (2012); (g) Singh et al. (2012); (h) Cavallo et al. (2013); (i) Maheswaran et al. (2013); (j) Christobel et al. (2011); (k) Lu et al. (2008); (l) Vairappan and Suzuki (2000); (m) Radhika et al. (2014); (n) Mata et al. (2013); (o) Kim et al. (2011); (p) El Ghany and Alla (2008); (q) Hutson et al. (2013)

Q3

range of antibacterial properties (Table 3). Interestingly, most studies were conducted in Asia (mainly India), while considerably fewer in other parts of the world, which can be associated with the extensive use of seaweed in the human diet in this area.

Fish bacterial pathogens

Antibacterial activities of seaweed extracts have been found against many Gram positive and Gram negative fish pathogenic bacteria, as many in vitro screenings have indicated (Table 3): many pathogenic *Vibrio* species, *Aeromonas hydrophila* and *Aeromonas salmonicida*, *Edwardsiella tarda*, *Renibacterium salmoninarum*, *Photobacterium damsela* sbsp *piscicida*, *Pseudomonas anguilliseptica*, *Streptococcus iniae* and *Yersinia ruckeri* (Vairappan and Suzuki 2000; Bansemir et al. 2004; 2006; Dubber and Harder 2008; Ganeshamurthy et al. 2012; Genovese et al. 2012; Rebecca et al. 2012; Singh et al. 2012; Cavallo et al. 2013; Maheswaran et al. 2013; Mata et al. 2013; Radhika et al. 2014).

Few of these studies investigated the potential of using seaweeds to control bacterial pathogens in the aquatic environment (Fig. 2). Lu et al. (2008) demonstrated the antimicrobial properties of *Ulva clathrata* in a series of experiments. In one experiment in particular, they added *V. anguillarum* in tanks containing cultures of the seaweed (10 g fresh algae L⁻¹). The seaweed significantly reduced the growth of the bacterium in the water. However, the study did not include any experiment with fish and thus the applicability of these findings was not assessed. Mata et al. (2013) examined both in vitro and in vivo the antibacterial effect of the aqueous extracts bromoform and dibromoacetic acid from the red seaweed *Asparagopsis taxiformis* against the fish pathogen *Streptococcus iniae*. In that study, the extracts were added into the water containing barramundi (*Lates calcarifer*) fingerlings already infected with *Streptococcus iniae*. The findings indicated that addition of approximately 28 µg L⁻¹ bromoform and 5 µg L⁻¹ dibromoacetic acid could delay the growth of the bacterium in the water, but did not affect significantly the mortalities caused by *Streptococcus iniae*. This study however examined the activity of the extracts after the infection, while the possible prophylactic effect prior to infection was not investigated. Addition of higher concentration of the extracts was more effective against the pathogen, but also induced mortality in the fish.

Shrimp bacterial pathogens

Almost all studies related to the antibacterial effects of seaweed extracts against shrimp pathogenic bacteria have focused on the bacterial genus *Vibrio* spp., as this represents the main bacterial group that can induce significant mortalities in shrimp farming (Defoirdt et al. 2006; Baleta et al. 2011;

462 Selvin et al. 2011; Dashtiannasab et al. 2012; Manilal et al.
463 2012; Cavalo et al. 2013; Silva et al. 2013; Sivakumar et al.
464 2014; Thanigaivel et al. 2014). When in vivo studies were
465 carried out, the extracts were delivered to the shrimp mainly
466 through enriched *Artemia* or medicated dry feeds. In one
467 study, the extracts were added into the water that contained
468 infected shrimp (Thanigaivel et al. 2014).

469 Traifalgar et al. (2009) examined and demonstrated the
470 overall protective effect of fucoidan extracted from *Undaria*
471 *pinnatifida* against *V. harveyi* in post-larvae black tiger shrimp
472 (*Penaeus monodon*). In that study, the shrimp that were fed
473 with 500–2,000 mg kg⁻¹ body weight for 1 month exhibited
474 significantly lower mortality when infected artificially with
475 the bacterial pathogen. Interestingly, the shrimp that were fed
476 with the medicated feeds also exhibited improved growth
477 performance. Selvin et al. (2011) confirmed the protective
478 effect of *U. fasciata* extracts after feeding black tiger shrimp
479 post-larvae with medicated feed for 2 weeks. Subsequently,
480 they challenged the shrimp with four pathogens, namely *Vib-*
481 *rio fischeri*, *V. harveyi*, *V. alginolyticus* and *Aeromonas* spp.
482 The group of shrimp fed with 1 g kg⁻¹ seaweed extract
483 exhibited significantly lower mortality. Similarly, Manilal
484 et al. (2012) examined the protective and therapeutic effect
485 of ethyl acetate partitioned fraction of *Asparagopsis* spp. in
486 black tiger shrimp post-larvae. For this, they fed the shrimp for
487 3 weeks and then challenged them with lethal doses of
488 *V. harveyi*, *V. alginolyticus*, *Vibrio parahaemolyticus* and
489 *Photobacterium damsela*. In this study, the authors examined
490 the therapeutic effect as the shrimp were also fed with the
491 medicated feed after the infection. Shrimp fed with 850 and 1,
492 150 mg kg⁻¹ exhibited significantly increased survival rate. In
493 all the above studies, the exact mode of action of the extracts
494 was not determined.

495 In some studies, the authors attempted to explain the pro-
496 tective effect of the extracts only through their
497 immunostimulatory properties. For example, Sirirustananun
498 et al. (2011) studied the immunostimulatory effect of hot-
499 water extract of *Gracilaria tenuistipitata* by feeding white
500 shrimp (*Litopenaeus vannamei*) with 0.5, 1.0, and 2.0 g kg⁻¹
501 dry diet for 14 days, before challenging them with
502 *V. alginolyticus* and White Spot Syndrome Virus. The extracts
503 induced a significant immunostimulatory effect and
504 increased survival rates. However, the study did not include
505 any in vitro antibacterial assays, to indicate any possible direct
506 antibacterial effect, which could also play an important role.

507 Kanjana et al. (2011) studied both in vitro and in vivo the
508 protective role of some solvent extracts of the red seaweed
509 *Gracilaria fisheri* against *V. harveyi*. After an initial screening
510 using a disc diffusion assay, the authors used only the ethanol
511 extracts for further in vivo studies. For the in vivo study, the
512 authors fed the shrimp with enriched *Artemia salina* instars II
513 (either with 0.5 or 1.0 mg mL⁻¹) for 2 weeks and then they
514 artificially infected shrimp post-larvae with the bacterial

515 pathogens. The results indicated both an antibacterial as well
516 as an immunostimulatory effect (i.e. increased total
517 haemocyte and granulocyte counts, increased phenoloxidase
518 (PO) and superoxide dismutase (SOD) activities and increased
519 super oxide anion production). Immanuel et al. (2004) also
520 studied in vitro and in vivo the protective role of some sea-
521 weeds extracts against the shrimp pathogen
522 *V. parahaemolyticus* by feeding *Penaeus indicus* post-larvae
523 with *Artemia franciscana* preadults enriched with 400 mg L⁻¹
524 of butanolic extracts from *Ulva lactuca* and *Sargassum*
525 *wightii*. In this study, the authors maintained the shrimp in
526 water containing the pathogen for 30 days, while fed them
527 with the seaweed extract-enriched *Artemia*. Interestingly, they
528 found that the extract that exhibited the highest inhibition zone
529 in the initial in vitro screening also induced reduced bacterial
530 load in the internal organs of the infected shrimp and increased
531 the survival rate.

532 Thanigaivel et al. (2014) conducted a study which has
533 demonstrated the potential of using seaweed extracts as alter-
534 natives to antibiotics. The authors examined the antioxidant
535 and antibacterial properties of an ethanol extract from the
536 green seaweed *Chaetomorpha antennina*. Regarding the anti-
537 bacterial properties, the authors first infected *Penaeus*
538 *monodon* (mean weight 12 g) with *V. parahaemolyticus* and
539 then treated the diseased shrimp by immersing them into water
540 containing 250 mg L⁻¹ of the seaweed extract for 12–48 h.
541 This treatment resulted in 98 % of survival of the treated
542 shrimp. In addition, i.m. injection of 25 µL of the extract per
543 shrimp protected the animals when they were subsequently
544 infected by the bacterial pathogen. This is the first report that
545 shows the therapeutic effect of a short-term administration of
546 seaweed extracts.

547 A recent study by Sivakumar et al. (2014) demonstrated
548 possible mechanisms that could explain the antimicrobial
549 properties of *U. fasciata* against the pathogen *V. harveyi*.
550 Thus, they demonstrated that solvent seaweed extracts re-
551 duced the phospholipase, proteolysis, lipolysis and
552 thermonuclease activities of treated bacteria. The study in-
553 cluded also an immersion challenge trial, in which *Penaeus*
554 *monodon* post-larvae were maintained in water containing
555 *V. harveyi* for 30 days. Addition of 200 µg mL⁻¹ of extracts
556 into the water resulted in significantly reduced mortality.

557 Defoirdt et al. (2006) examined the antibacterial effect of
558 halogenated furanone extracted from the red seaweed *Delisea*
559 *pulchra* against the shrimp bacterial pathogens *Vibrio*
560 *campbellii*, *V. harveyi* and *V. parahaemolyticus*. They reported
561 that this natural product at the concentration of 20 mg L⁻¹
562 could protect in vivo the brine shrimp *Artemia franciscana*
563 against these bacterial pathogens, although the substance did
564 not have any effect on the growth rate of the pathogens in the
565 water. Higher concentrations were toxic to *Artemia*. The au-
566 thors concluded that the protective effect was probably due to
567 the disruption of the quorum sensing mechanism, as assessed

Table 2 Assessment of the antimicrobial properties of seaweed extracts against shrimp pathogens

	Seaweed genus/species	Extraction method	Shrimp species	In vitro assays	In vivo assays	Pathogen	Results
t2.1	Bacterial						
t2.2							
t2.3	<i>Undaria pinnatifida</i> (a) (brown)	Organic solvents	<i>Penaeus monodon</i>	–	Feeding trial and immersion challenge	<i>Vibrio harveyi</i>	Reduced mortality
t2.4	<i>Ulva fasciata</i> (b) (green)	Organic solvents	<i>Penaeus monodon</i>	–	Feeding trial and injection challenge	<i>Vibrio alginolyticus V. harveyi</i>	Reduced mortality
t2.5	<i>Asparagopsis</i> spp. (c) (red)	Organic solvents	<i>Penaeus monodon</i>	–	Feeding trial and injection challenge	<i>Aeromonas</i> spp. <i>Vibrio harveyi</i> <i>Vibrio alginolyticus</i> <i>Vibrio parahaemolyticus</i>	Reduced mortality
t2.6	<i>Gracilaria tenuistipitata</i> (d) (red)	Water	<i>Litopenaeus vannamei</i>	–	Feeding trial and injection challenge	<i>Photobacterium damsela</i> <i>Vibrio alginolyticus</i>	Reduced mortality
t2.7	<i>Gracilaria fisheri</i> (e) (red)	Organic solvents	<i>Penaeus monodon</i>	Disc diffusion assay Minimum inhibitory concentrations	Safety test for the seaweed ethanol extract Enrichment of <i>Artemia salina</i> Immersion challenge of shrimp post-larvae and juveniles	<i>Vibrio harveyi</i>	In vitro antibacterial effect Reduced mortality
t2.8	<i>Ulva lactuca</i> (f) (green) <i>Sargassum wightii</i> (f) (brown)	Organic solvents	<i>Penaeus indicus</i>	Disc diffusion assay	Enrichment of <i>A. salina</i> Immersion challenge of shrimp juveniles	<i>Vibrio parahaemolyticus</i>	In vitro antibacterial effect Reduced bacterial load in the internal organs Reduced mortality
t2.9	<i>Delisea pulchra</i> (g) (red) Synthetic furanone (g)	Organic solvents	<i>Artemia franciscana</i>	Growth inhibition of furanone in liquid growth medium and water (plate counts) Disruption of AI-2 quorum sensing by synthetic furanone	Addition of the extract into the water and challenge tests	<i>Vibrio harveyi</i> <i>Vibrio campbellii</i> <i>Vibrio parahaemolyticus</i>	Disruption of the quorum sensing mechanism Reduced mortality
t2.10	<i>Sargassum polycystum</i> (h) (brown)	Water	<i>Penaeus monodon</i>	Agar diffusion assay Minimum inhibitory concentrations	Feeding trial and incubation challenge	<i>Vibrio harveyi</i>	Reduced mortality
t2.11	<i>Ulva fasciata</i> (i) (green)	Organic solvents	<i>Penaeus monodon</i>	Agar well diffusion assay Minimum inhibitory concentrations Effect on virulence factors	Immersion challenge	<i>Vibrio harveyi</i>	In vitro antibacterial effect Reduced activity of many virulence factors Reduced mortality
t2.12	<i>Delisea pulchra</i> (j) (red)	Organic solvents	<i>Penaeus monodon</i>	Inhibition of luminescence T1 toxin production	Toxicity of supernatant extracts from furanone-treated <i>V. harveyi</i> cultures assess by i.m. injection	<i>Vibrio harveyi</i>	Inhibition of luminescence and T1 toxin production Reduced mortality
t2.13	<i>Chaetomorpha antennina</i> (k) (green)	Organic solvents	<i>Penaeus monodon</i>	Well diffusion method	Immersion treatment after i.m. and immersion challenge i.m. injection of extract followed by infection	<i>Vibrio parahaemolyticus</i> ,	In vitro antibacterial effect Therapeutic effect after challenge

t2.14 **Table 2** (continued)

	Seaweed genus/species	Extraction method	Shrimp species	In vitro assays	In vivo assays	Pathogen	Results
t2.14	<i>Padina gymnospora</i> (l) (brown)	Organic solvents	–	Disc diffusion assay	–	<i>Vibrio parahaemolyticus</i> , <i>Vibrio brasiliensis</i> , <i>Vibrio xuii</i> , <i>Vibrio navarrensis</i>	Improved histological picture after treatment with the extracts Protective effect of the i.m. injection of the extract In vitro antibacterial effect
t2.15	<i>Sargassum oligocystum</i> (m) (brown)	Organic solvents	–	Disc diffusion method	–	<i>Vibrio alginolyticus</i> , <i>Vibrio parahaemolyticus</i> <i>Vibrio harveyi</i>	In vitro antibacterial effect
t2.16	<i>Sargassum latifolium</i> (brown)	Organic solvents	–	Disc diffusion method	–	<i>Vibrio alginolyticus</i> , <i>Vibrio parahaemolyticus</i> <i>Vibrio harveyi</i>	In vitro antibacterial activity Reduced mortality
t2.17	Viral <i>Sargassum wightii</i> (o) (brown)	Organic solvents	–	–	Enrichment of <i>Artemia</i> nauplii with fucooidan Immersion challenge Enrichment of <i>A. salina</i> Immersion challenge of shrimp post-larvae	White Spot Syndrome Virus	Reduced mortality
t2.18	<i>Sargassum wightii</i> (p) (brown) <i>Sargassum duplicatum</i> (p) (brown) <i>Sargassum wightii</i> (q) (brown)	Water	<i>Penaeus monodon</i>	–	–	White Spot Syndrome Virus	Reduced mortality
t2.19	<i>Sargassum wightii</i> (q) (brown)	Organic solvents	<i>Penaeus monodon</i>	–	Enrichment of <i>Artemia franciscana</i> nauplii Immersion challenge Viral load using nested PCR	White Spot Syndrome Virus	Reduced mortality
t2.20	<i>Sargassum polycystum</i> (h) (brown)	Water	<i>Penaeus monodon</i>	–	Feeding trial and immersion challenge	White Spot Syndrome Virus	Reduced mortality
t2.21	<i>Aerosiphonia orientalis</i> (r) (green)	Organic solvents	<i>Penaeus monodon</i>	–	Feeding trial and immersion challenge	White Spot Syndrome Virus	Reduced mortality
t2.22	<i>Cladosiphon okamuranus</i> (s) (brown)	–	<i>Penaeus japonicus</i>	–	Feeding trial and immersion challenge	White Spot Syndrome Virus	Reduced mortality
t2.23	<i>Sargassum wightii</i> (t) (brown)	Water	<i>Penaeus indicus</i> <i>Paratetaphusa hydrodomous</i>	–	Determination of viral inactivation using i.m. injection of shrimp	White Spot Syndrome Virus	Reduced mortality
t2.24	<i>Gracilaria tenuistipitata</i> (d) (red)	Water	<i>Litopenaeus vannamei</i>	–	Feeding trial and injection challenge	White Spot Syndrome Virus	Reduced mortality

References: (a) Traifalgar et al. (2009); (b) Selvin et al. (2011); (c) Manilal et al. (2012); (d) Sirirustananun et al. (2011); (e) Kanjana et al. (2011); (f) Immanuel et al. (2004); (g) Defoirdt et al. (2006); (h) Chotigeat et al. (2004); (i) Sivakumar et al. (2014); (j) Manefield et al. (2000); (k) Thanigaivel et al. (2014); (l) Silva et al. (2013); (m) Baleta et al. (2011); (n) Dashtianmasab et al. (2012); (o) Sivagnanavelmurugan et al. (2012); (p) Immanuel et al. (2010); (q) Immanuel et al. (2012); (r) Manilal et al. (2012); (s) Takahashi et al. (1998); (t) Balasubramanian et al. (2006)




Fig. 2 Modes of administration of the seaweed extracts in fish and shrimp farming

568 by inhibition of bioluminescence, although a possible interaction
 569 between furanone and the shrimps was not excluded.
 570 Earlier, Manefield et al. (2000) had found that there is a link
 571 between bioluminescence and toxin production in *V. harveyi*
 572 and that the furanone that Defoirdt et al. (2006) also used
 573 could decrease the production of toxin by the bacterium. They
 574 also observed a protective effect in *P. monodon*, when they
 575 injected intramuscularly the animals with furanone-treated
 576 *V. harveyi* cultures. Rasch et al. (2004) examined the potential
 577 of using a synthetic halogenated furanone at significantly
 578 lower concentration ($2.5 \mu\text{g L}^{-1}$) to minimize the mortality
 579 caused by *V. anguillarum* in rainbow trout (*Oncorhynchus*
 580 *mykiss*). Although no natural seaweed extracts were used,
 581 the use of synthetic furanone decreased the mortality caused
 582 by the bacterial pathogen, probably through the disruption of
 583 the quorum sensing mechanism. As in the study by Defoirdt
 584 et al. (2006), no effect of the synthetic furanone were observed
 585 on the growth, the survival, the respiratory activity and the
 586 motility of the bacterium.

587 Viral pathogens

588 Currently, no antiviral drugs are used in aquaculture and thus
 589 the study of any substance with antiviral properties that can be
 590 used against fish or shellfish viruses is of great importance.
 591 The strategies that are currently used in aquaculture to control
 592 viral diseases rely on the use of effective vaccines (mostly in

fish farming) and the development of lines of animals resistant
 593 to certain diseases through selective breeding (Kibenge et al.
 594 2012). In shrimp farming, oral administration of
 595 immunostimulants has been suggested as a particularly prom-
 596 ising method against viral pathogens (Sivagnanavelmurugan
 597 et al. 2012), as vaccination is a rather experimental control
 598 method (Sudheer et al. 2012).
 599

The antiviral properties of seaweed extracts against human
 600 viruses are well reported. Various water-soluble extracts from
 601 red, brown and green seaweeds and particularly sulphated
 602 polysaccharides, exhibit antiviral properties against many vi-
 603 ruses, such as the herpes simplex viruses (Saha et al. 2012;
 604 Son et al. 2013), the Japanese encephalitis virus (flavivirus)
 605 (Chiu et al. 2012) and the influenza virus (Jiao et al. 2012).
 606 The antiviral activities against human viruses have been
 607 assessed mainly by in vitro studies, on cell lines, but also by
 608 in vivo studies, using experimental animals (e.g. mice). These
 609 studies have shown that the extracts can suppress the replica-
 610 tion of the viruses, and delay the manifestation of the disease
 611 symptoms, increasing the survival rates of the infected ani-
 612 mals. The active substances found in seaweed extracts include
 613 among others: sulphoglycolipids, carrageenans and fucoidans
 614 (Mohamed et al. 2012). The mode of action depends on the
 615 substance but also on the virus. For instance, many sulphated
 616 polysaccharides may bind to the surface of the viruses (mainly
 617 enveloped viruses), or to virus receptors on the host cell
 618 surface, thus interfering with the attachment and the
 619

- 620 adsorption of the viruses to the host cells (Wang et al. 2012).
 621 Some carrageenans can also exhibit post-binding inhibitory
 622 effects, affecting the intracellular stages of the infection (Buck
 623 et al. 2006), and particularly the virus transcription and repli-
 624 cation (Wang et al. 2012). Factors that may affect the antiviral
 625 properties of the sulphated polysaccharides include the sugar
 626 composition, the main chain length, the sulphation level and
 627 the sulphate pattern (Jiao et al. 2012). Phlorotannins from the
 628 brown seaweed *Ecklonia cava* were also found to exhibit
 629 inhibitory effect on HIV-1 reverse transcriptase and proteases
 630 (Ahn et al. 2004).
- 631 Currently, there is only one study that indicates a possible
 632 protective effect of seaweed extracts against fish viruses (In-
 633 fectious Hematopoietic Necrosis Virus and Infectious Pancre-
 634 atic Necrosis Virus), while there are many studies on White
 635 Spot Syndrome Virus of shrimp. In contrast to bacterial patho-
 636 gens, both water and organic solvents were used for the
 637 extraction (Table 2). The seaweed species that exhibited the
 638 antiviral activity were as follows: for WSSV: red seaweeds—
 639 *G. tenuistipitata*, brown seaweeds—*Sargassum* spp. and
 640 *Cladosiphon okamuranus*, green seaweeds—*Acrosiphonia*
 641 *orientalis*; and for IHNV and IPNV—the red seaweed
 642 *Polysiphonia morrowii* (Table 3). All studies discussed in
 643 the present review took place in Asia, probably because there
 644 is an increased interest to develop effective control strategies
 645 against WSSV, as no effective vaccines are yet available for
 646 the shrimp industry.
- 647 *Fish viral pathogens*
- 648 Kim et al. (2011) used cell-based assay to assess the antiviral
 649 properties of the red alga *Polysiphonia morrowii*. They found
 650 that the 80 % (v/v) methanolic extract had significant antiviral
 651 activity against two important fish viruses, the Infectious
 652 Hematopoietic Necrosis Virus (IHNV—family
 653 Rhabdoviridae) and the Infectious Pancreatic Necrosis Virus
 654 (IPNV—family Birnaviridae). Although, the study was
 655 in vitro and the authors did not provide any evidence on the
 656 mechanism of action of these extracts on the viruses, the
 657 results indicate the potential of using seaweed extracts against
 658 these viruses.
- 659 *Shrimp viral pathogens*
- 660 The White Spot Syndrome Virus (WSSV—family
 661 Nimaviridae) is the major pathogen affecting the shrimp pro-
 662 duction worldwide. WSSV can induce up to 100 % mortality
 663 within a few days, particularly at larval and juvenile stages.
 664 Various authors studied therefore the antiviral properties of the
 665 seaweed extracts in particular against the WSSV by adminis-
 666 trating the extracts to shrimp either via enriched *Artemia*
 667 nauplii (Immanuel et al. 2010; Immanuel et al. 2012;
 668 Sivagnanavelmurugan et al. 2012) or through medicated feeds
 (Chotigeat et al. 2004; Manilal et al. 2009). Based on these
 studies, the effective concentration of extracts that can be used
 to enrich *Artemia* ranges from 400 to 750 mg L⁻¹, while the
 shrimp should be fed for about 20 days prior in order to acquire
 protection against the virus. On the other hand, medicated
 feeds were efficient when the seaweed extracts were added
 at a concentration of 250–500 mg kg⁻¹ body weight. The
 active components were found to be polysaccharides, in par-
 ticular fucoidans and sodium alginates (Takahashi et al. 1998;
 Chotigeat et al. 2004; Manilal et al. 2009; Immanuel et al.
 2012; Sivagnanavelmurugan et al. 2012). Chotigeat et al.
 (2004) examined in particular the prophylactic and therapeutic
 effect of crude fucoidan extracted from *Sargassum polycystum*
 against WSSV. Black tiger shrimps of different sizes were fed
 with medicated feed 4 days prior to and 10 days after an
 experimental infection. The results showed that crude
 fucoidan at the concentration of 400 mg kg⁻¹ of body weight
 day⁻¹ increased significantly the survival rate, while at the
 same time increased the phagocytic activity of the shrimp
 haemocytes. Similar results were obtained in an earlier study
 by Takahashi et al. (1998) who fed kuruma shrimp (*Penaeus*
japonicus) with fucoidan extracted from the brown seaweed
C. okamuranus, at the concentration of 100 mg kg⁻¹ of body
 weight day⁻¹.
- In another study by Balasubramanian et al. (2006), the
 extracts, after their extraction by either water or organic sol-
 vents, were first mixed with suspensions of WSSV in order to
 de-activate the virus. Subsequently, the treated viral prepara-
 tions were injected intramuscularly into marine shrimp
(Penaeus indicus) and freshwater crab (*Paratelphusa*
hydrodomous). Aqueous extracts of *Sargassum weightii* at a
 concentration of 3 mg per animal resulted in significantly less
 mortality in the infected animals.
- In all the above studies on WSSV, the mechanisms
 explaining the antiviral action of these seaweed extracts were
 not determined. However, apart from the immunostimulatory
 effects, a direct antiviral effect of the extracts similar to that
 observed in other viruses cannot be excluded as a study by
 Rudtanatip et al. (2014) indicates. These authors reported that
 sulphated galactans isolated from the red seaweed *G. fisheri*
 attached to certain sites on the viral envelope and hence
 inhibited the attachment of the viruses to the host cells.
- Parasitic pathogens
- The antiparasitic properties of many seaweed extracts have
 been studied on a wide range of human parasites, such as
 protozoa (e.g. *Plasmodium* spp. and *Trichomonas* spp.) (Moo-
 Puc et al. 2008; Vonthron-Sénécheau et al. 2011), helminthes
 (e.g. *Ascaris* spp.) (Higa and Kuniyoshi 2000) and insects
 (e.g. mosquito larvae) (Bianco et al. 2013). The mechanism
 of action varies according to the extracts and the parasites.
 Thus, the extracts can either interfere with the binding of the

Table 3 Seaweed species tested against fish and shrimp pathogens. The table summarizes the findings presented in Tables 1 and 2 of this review

t3.2	Seaweed genus/species	Geographical area	Pathogen
t3.3	Red seaweeds		
t3.4	<i>Asparagopsis armata</i>	Atlantic, France	Vang, Pang, Asal, Ahyd, Yruc
t3.5	<i>Asparagopsis taxiformis</i>	Italy	Valg, Vpar, Vhar, Vvul, Asal, Pdad, Pdap,
t3.6	<i>Asparagopsis taxiformis</i>	Australia	Sini, Neo
t3.7	<i>Ceramium rubrum</i>	North Sea	Asal, Valg, Yruc
t3.8	<i>Delisea pulchra</i>	India	Vhar, Vcam, Vpar
t3.9	<i>Delisea pulchra</i>	Australia	Vhar
t3.10	<i>Gracilaria corticata</i>	India	Vpar, Ahyd, Valg, Vhar, Vfis
t3.11	<i>Gracilaria dura</i>	Italy	Vord, Valg
t3.12	<i>Gracilaria fisheri</i>	Thailand	Vhar
t3.13	<i>Gracilaria gracilis</i>	Italy	Vsal
t3.14	<i>Gracilaria tenuistipitata</i>	Taiwan	Valg, WSSV
t3.15	<i>Gracilariopsis longissima</i>	Southern Italy	Valg, Vvul
t3.16	<i>Hypnea musciformis</i>	India	Vhar, Vfis
t3.17	<i>Laurencia chondrioides</i>	Gran Canaria	Vang, Pang, Asal, Ahyd, Yruc, Pdapi
t3.18	<i>Mastocarpus stellatus</i>	North Sea	Asal, Vang
t3.19	<i>Polysiphonia morrowii</i>	South Korea	IHNV, IPNV
t3.20	Green seaweeds		
t3.21	<i>Acrosiphonia orientalis</i>	India	WSSV
t3.22	<i>Caulerpa racemosa</i>	India	Vpar, Ahyd
t3.23	<i>Caulerpa sertulrioides</i>	India	Vpar, Ahyd
t3.24	<i>Chaetomorpha antennina</i>	India	Vpar, Ahyd
t3.25	<i>Chaetomorpha linum</i>	Southern Italy	Vvul, Vord
t3.26	<i>Chladophora rupestris</i>	Southern Italy	Vvul, Vsal, Vord
t3.27	<i>Codium tomentosum</i>	India	Valg, Vhar, Vfis
t3.28	<i>Halimeda micronesia</i>	India	Valg, Vpar, Ahyd, Etar
t3.29	<i>Ulva clathrata</i>	China	Vang
t3.30	<i>Ulva fasciata</i>	India	Valg, Vhar, Vfis, Aero
t3.31	<i>Ulva prolifera</i>	Southern Italy	Vord
t3.32	<i>Ulva lactuca</i>	India	Vpara
t3.33	<i>Ulva reticulata</i>	Malaysia	Valg, Vpar, Ahyd
t3.34	<i>Ulva</i> spp.	Australia	Neo
t3.35	Brown seaweeds		
t3.36	<i>Cladosiphon okamuranus</i>	Japan ^a	WSSV
t3.37	<i>Dictyota dichotoma</i>	India	Valg
t3.38	<i>Fucus vesiculosus</i>	Egypt ^a	Icth
t3.39	<i>Laminaria digitata</i>	North Sea	Vang, Pdad, Yruc
t3.40	<i>Padina gymnospora</i>	India	Vpar, Ahyd, Valg,
t3.41	<i>Padina gymnospora</i>	Brazil	Vpar, Vbra, Vxui, Vnav

Table 3 (continued)

Seaweed genus/species	Geographical area	Pathogen	
<i>Padina tetrastomatica</i>	India	Valg, Vhar, Etar, Ahyd	t3.43
<i>Sargassum duplicatum</i>	India	WSSV	t3.44
<i>Sargassum latifolium</i>	Persian Gulf	Vpar, Valg, Vhar	t3.45
<i>Sargassum oligocystum</i>	Philippines	Vpar, Valg, Vhar	t3.46
<i>Sargassum polycystum</i>	Thailand	Vhar, WSSV	t3.47
<i>Sargassum wightii</i>	India	Vpar, Ahyd, Valg, Vhar, Vfis, Rsal, WSSV	t3.48
<i>Stoechospermum marginatum</i>	India	Ahyd	t3.49
<i>Undaria pinnatifida</i>	Japan	Vhar	t3.50
<i>Turbinaria ornata</i>	India	Rsal	t3.51

The relevant references are cited in Tables 1 and 2

Aero Aeromonas spp., *Ahyd Aeromonas hydrophila*, *Asal Aeromonas salmonicida*, *Etar Edwardsiella tarda*, *Icth I. hoferi*, *IHNV* Infectious Hematopoietic Necrosis Virus, *IPNV* Infectious Pancreatic Necrosis Virus, *Neo Neobenedenia* spp., *Pang Pseudomonas anguilliseptica*, *Pdad Photobacterium damsela* sbsp *damsela*, *Pdap Photobacterium damsela* sbsp *piscicida*, *Rsal R. salmoninarum*, *Sini Streptococcus iniae*, *Valg V. alginolyticus*, *Vang V. anguillarum*, *Vbra Vibrio brasiliensis*, *Vcam Vibrio campelii*, *Vfis V. fisheri*, *Vhar V. harveyi*, *Vord Vibrio ordalii*, *Vpar V. parahaemolyticus*, *Vsal Vibrio salmonicida*, *Vvul Vibrio vulnificus*, *Vxui Vibrio xuii*, *WSSV* White Spot Syndrome Virus, *Yruc Y. ruckeri*

^a Area where the study took place

parasites to the target host cells and the subsequent invasion (Patel 2012) or have a direct toxic effect on the parasites. For example, Moo-Puc et al. (2008) demonstrated the direct antiprotozoan activity of organic extracts derived from many seaweed species against *Trichomonas vaginalis* trophozoites, while Bianco et al. (2013) reported significant larvicidal activity of the red seaweed *Laurencia dendroidea* organic extracts against the larval stages of the mosquito *Aedes aegypti*. Despite the many studies on human parasites, the information on the antiparasitic properties of seaweeds against fish parasites is limited, while there are no published studies on shrimp parasites.

Hutson et al. (2012) examined the effect of aqueous extracts from two seaweeds *Ulva* spp. and *Asparagopsis taxiformis* on the parasitism of barramundi (*L. calcarifer*) by the monogenean ectoparasite *Neobenedenia* spp. The extracts, at the concentration of 1/100 v/v, mainly affected the initial stages of the cycle of the parasites. In particular, they inhibited the embryonic development, delayed the time of first and last hatching, and reduced the hatching success rate of the parasite. The *Asparagopsis taxiformis* extracts appeared substantially more effective. Both extracts however had no significant effect on the survival of the attached adult parasites or the

743 infection success of oncomiracidia. The authors suggested that
744 these extracts could be particularly effective in either closed or
745 integrated farming systems, if these seaweed species are co-
746 cultivated along with the fish. There was however no assess-
747 ment of the applicability of this method under farming
748 conditions.

749 Ghany and Alla (2008) reported that when Nile tilapias
750 (*Oreochromis niloticus*) experimentally infected with the pro-
751 tozoan fish endoparasite *Ichthyophonus hoferi*, they exhibited
752 reduced mortality when fed post-infection with extracts from
753 the seaweed *Fucus vesiculosus* (2 g kg⁻¹ body weight) for
754 3 months. It should be noted though that the study did not
755 provide adequate information on the characteristics of the
756 extracts, or how they were produced.
757

758 Conclusions and future priorities

759 Aquaculture is a growing industry and infectious diseases
760 constitute one of the main limiting factors, affecting the pro-
761 duction volume and cost. Assessment of the exact effects of
762 the microbial diseases on the aquaculture production is very
763 difficult, as there are direct and indirect effects. Stressful
764 conditions can also compromise the immune system of fish
765 and shellfish and subsequently reduce their response to any
766 infectious agent (Huntingford et al. 2006).

767 Seaweeds represent a group of aquatic organisms which is
768 an important part of the marine food chain, as well as the
769 human diet. In addition to their nutritional value, they also
770 exhibit antimicrobial, immunostimulatory and antioxidant
771 properties. In the last 20 years, there is an increasing interest
772 in using various seaweed extracts as prophylactic and thera-
773 peutic agents in aquaculture.

774 Although there are fewer published studies on fish and
775 shrimp pathogens compared to human and husbandry animal
776 pathogens, the findings indicate that seaweeds can play an
777 important role in the upcoming aquaculture sustainable
778 practices.

779 There are few published studies, which included both
780 in vivo and in vitro assessment of the direct antimicrobial
781 properties of seaweeds. Regarding the fish pathogens, almost
782 all published information comes from in vitro screenings,
783 where extracts of different seaweed species were tested
784 against many bacterial pathogens, while there is only one
785 published study on fish viruses (IHNV and IPNV) and two
786 on fish parasites (*I. hoferi* and *Neobenedenia* spp.). Interest-
787 ingly, there are no published studies on salmon and carps, which
788 are extensively farmed. The studies on shrimp have focused
789 on the antimicrobial effects of seaweed extracts mainly against
790 many *Vibrio* species and WSSV. Although all the studies
791 indicate the overall positive effect of the extracts, they do
792 not elucidate the exact mechanism of action and particularly

793 within the animal tissues (Fig. 1). Furthermore, although it is
794 known that many seaweed extracts also exhibit
795 immunostimulatory properties, which can contribute to the
796 protective effect, in most studies these effects were never
797 examined in parallel to the antimicrobial effects.

798 In general terms, all three groups of seaweeds (red, green
799 and brown) exhibit antimicrobial properties, but the genera
800 that appear to exhibit a broader range of activity are
801 *Asparagopsis* spp. (red) and *Sargassum* spp. (brown). It
802 should be noted though that comparison between species is
803 difficult, as there are many factors that can affect the anti-
804 microbial properties, and the same seaweed species may exhibit
805 different properties depending on the season or the geograph-
806 ical area.

807 The extraction method is also an important factor that can
808 affect the efficacy of the produced extracts. In 27 out of 39
809 the studies that are presented in this review, organic solvents
810 were used for the extraction rather than water.

811 The modes of delivery of the active seaweed substances
812 can either be through the water (released directly from the
813 seaweeds or added into it after their extraction), or through
814 medicated feed (again after their extraction), as outlined in
815 Fig. 2. In the first case, mainly water-soluble substances of
816 seaweeds can be released or added into the aquatic environ-
817 ment of the farmed fish and shrimp. These substances appear
818 to affect the quorum sensing mechanism in bacteria with
819 limited effects on the bacterial growth. When the extracts are
820 added into the feeds (live or dry), they can act directly against
821 the pathogens or by stimulating the immune system. In addi-
822 tion, there are no complete pharmacodynamic and pharmaco-
823 kinetic studies, which can demonstrate the exact mode of
824 action of any seaweed extract. This important issue should
825 be included in future studies.

826 An important point that none of the published studies
827 presented in our review has examined is the applicability of
828 using any of these extracts on a commercial scale. The main
829 issues related to this are the extraction cost and how the
830 extracts can be delivered to fish or shrimp under the intensive
831 farming conditions.

832 The production cost of seaweeds varies according to the
833 country and it can be between € 160 and € 330 T⁻¹ dry, in Asia
834 and Europe, respectively, but new seaweed culture techniques
835 are expected to reduce this cost (Bruton et al. 2009). For the
836 extraction of the active substances, there are a few methods
837 that are available on a commercial scale and at the moment the
838 cost of these methods is relatively high (Takahashi et al. 1998;
839 Ibañez et al. 2012). The yield of the active substances extract-
840 ed from seaweed is between less than 1 % up to 40 % of the
841 dry algal mass, depending on various factors, such the metabo-
842 lite, seaweed species and season (Pereira and Costa-Lotufu
843 2012). Possible solutions to the high production cost can be
844 the production of synthetic seaweed active compounds, as
845 some of them exhibit properties similar to the natural

846 substance (Rasch et al. 2004; Defoirdt et al. 2006), or the incor-
 847 poration of the responsible seaweed genes into microorganism
 Q6 848 as Pereira et al. (2012) suggested. However, some of these
 849 techniques have many complex steps and can be applied only
 850 when the antimicrobial effect of the natural analogs is well
 851 demonstrated.

852 As discussed before, one mode of action is through the
 853 inhibition of the quorum sensing mechanism of the bacterial
 854 pathogens that exist in the water column, prior to infection.
 855 The active substances need to be constantly added into the
 856 water for long periods, as Rasch et al. (2004) did during their
 857 experimental challenges. Mata et al. (2013) examining the
 858 therapeutic effect of seaweed extracts also added the extracts
 859 to the water containing infected fish for a long period. In
 860 practice, this method can only be applied on land facilities,
 861 when fish are reared in small tanks and the water exchange
 862 rate is low (e.g. in hatcheries). In addition, the administration
 863 of therapeutics extracted from seaweed must be monitored
 864 continuously, as sudden increases of the concentration of the
 865 antimicrobial substance can be lethal (Rasch et al. 2004; Mata
 866 et al. 2013) and exposure periods must be as short as possible
 867 (Thanigaivel et al. 2014). More studies on short-term expo-
 868 sures are therefore required to confirm the efficacy of such
 869 treatments, particularly against parasitic pathogens.

870 The safest delivery method reported is through medicated
 871 feed, as the dose of the extract per animal treated can be
 872 calculated more accurately. This method applies to all farming
 873 systems and can decrease the bacterial load in the tissues
 874 (Immanuel et al. 2004). Thus, this method of delivery will
 875 probably be the most effective and applicable one. Neverthe-
 876 less, more studies investigating the effect seaweed extracts on
 877 pathogens are necessary to support this hypothesis.

878 References

- 880 Aarestrup FM, Jensen VF, Emborg HD, Jacobsen E, Wegener HC (2010)
 881 Changes in the use of antimicrobials and the effects on productivity
 882 of swine farms in Denmark. *Am J Vet Res* 71:726–33
- 883 Abu-Ghannam N, Rajauria G (2013) Antimicrobial activity of com-
 884 pounds isolated from algae. In: Domínguez H (ed) *Functional in-*
 885 *gredients from algae for foods and nutraceuticals*. Woodhead,
 886 Sawston, pp 287–306
- 887 Ahn MJ, Yoon KD, Min SY, Lee JS, Kim JH, Kim TG, Kim SH, Kim
 888 NG, Huh H, Kim J (2004) Inhibition of HIV-1 reverse transcriptase
 889 and protease by phlorotannins from the brown alga *Ecklonia cava*.
 890 *Biol Pharm Bull* 27:544–547
- 891 Al-Hafedh YS, Alam A, Buschmann AH, Fitzsimmons KM (2012)
 892 Experiments on an integrated aquaculture system (seaweeds and
 893 marine fish) on the Red Sea coast of Saudi Arabia: efficiency
 894 comparison of two local seaweed species for nutrient biofiltration
 895 and production. *Rev Aquac* 4:21–31
- 896 Bailey SE, Olin TJ, Bricka RM, Adrian DD (1999) A review of poten-
 897 tially low-cost sorbents for heavy metals. *Water Res* 33:2469–2479
- Balasubramanian G, Sudhakaran R, Syed Musthaq S, Sarathi M, Sahul 898
 Hameed AS (2006) Studies on the inactivation of white spot syn- 899
 drome virus of shrimp by physical and chemical treatments, and 900
 seaweed extracts tested in marine and freshwater animal models. *J* 901
Fish Dis 29:569–572 902
- Baleta FN, Laureta LV, Apines-Amar MJS, Padilla PIP, Quintio GF 903
 (2011) Biological activity of extracts of *Sargassum oligocystum* 904
 (Magnaye) against aquaculture pathogenic bacteria. *Isr J Aquac* 905
IIC 63(2011):667 906
- Bansemir A, Just N, Michalik M, Lindequist U, Lalk M (2004) Extracts 907
 and sesquiterpene derivatives from the red alga *Laurencia* 908
chondrioides with antibacterial activity against fish and human 909
 pathogenic bacteria. *Chem Biodivers* 1:463–467 910
- Bansemir A, Blume M, Schröder S, Lindequist U (2006) Screening of 911
 cultivated seaweeds for antibacterial activity against fish pathogenic 912
 bacteria. *Aquaculture* 252:79–84 913
- Barrington K, Chopin T, Robinson S (2009) Integrated multi-trophic 914
 aquaculture (IMTA) in marine temperate waters. In: D. Soto (ed). 915
Integrated mariculture: a global review. FAO Fisheries and 916
 Aquaculture Technical Paper. No. 529. Rome, FAO, pp 7–46 917
- Bianco EM, Pires L, Santos GKN, Dutra KA, Reis TNV, Vasconcelos 918
 ERTPP, Cocentino ALM, Navarro DMAF (2013) Larvicidal activity 919
 of seaweeds from northeastern Brazil and of a halogenated sesqui- 920
 terpene against the dengue mosquito (*Aedes aegypti*). *Ind Crop Prod* 921
 43:270–275 922
- Bindu MS, Sobha V (2004) Conversion efficiency and nutrient digesti- 923
 bility of certain seaweed diets by laboratory reared *Labeo rohita* 924
 (Hamilton). *Indian J Exp Biol* 42:1239–1244 925
- Bruton T, Lyons H, Lerat Y, Stanley M, Rasmussen MB (2009) A review 926
 of the potential of marine algae as a source of biofuel in Ireland. 927
 Report prepared for Sustainable Energy Ireland. [http://www.seai.ie/](http://www.seai.ie/Publications/Renewables_Publications/_Bioenergy/Algaereport.pdf) 928
[Publications/Renewables_Publications/_Bioenergy/Algaereport.](http://www.seai.ie/Publications/Renewables_Publications/_Bioenergy/Algaereport.pdf) 929
[pdf](http://www.seai.ie/Publications/Renewables_Publications/_Bioenergy/Algaereport.pdf). Accessed 30 Oct 2014 930
- Buchholz CM, Krause G, Buck BH (2012) Seaweed and man. In: 931
 Wiencke C, Bischof K (eds) *Seaweed biology*. Springer, Berlin, pp 932
 471–493 933
- Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT 934
 (2006) Carrageenan is a potent inhibitor of papillomavirus infection. 935
PLoS Pathog 2(7):e69 936
- Burridge L, Weis J, Cabello F, Pizarro J, Bostick K (2010) Chemical use 937
 in salmon aquaculture: a review of current practices and possible 938
 environmental effects. *Aquaculture* 306:7–23 939
- Cai J, Feng J, Xie S, Wang F, Xu Q (2014) *Laminaria japonica* extract, an 940
 inhibitor of *Clavibacter michiganense* subsp. *sepedonicum*. *PLoS* 941
One 9(4):e94329 942
- Caipang CMA, Lazado CC, Berg I, Brinchmann MF, Viswanath K 943
 (2011) Influence of alginic acid and fucoidan on the immune res- 944
 ponses of head kidney leukocytes in cod. *Fish Physiol Biochem* 37: 945
 603–612 946
- Cavallo RA, Acquaviva M, Stabili L, Cecere E, Petrocelli A, Narracci M 947
 (2013) Antibacterial activity of marine macroalgae against fish 948
 pathogenic *Vibrio* species. *Cent Eur J Biol* 8:646–653 949
- Chiu YH, Chan YL, Li TL, Wu CJ (2012) Inhibition of Japanese 950
 encephalitis virus infection by the sulfated polysaccharide extracts 951
 from *Ulva lactuca*. *Mar Biotech* 14:468–478 952
- Chotigeat W, Tongsupa S, Supamataya K, Phongdara A (2004) Effect of 953
 fucoidan on disease resistance of black tiger shrimp. *Aquaculture* 954
 233:23–30 955
- Christobel JG, Lipton AP, Aishwarya MS, Sarika AR, Udayakumar A 956
 (2011) Antibacterial activity of aqueous extract from selected 957
 macroalgae of southwest coast of India. *Seaweed Res Util* 33:67–75 958
- Costello MJ (2009) The global economic cost of sea lice to the salmonid 959
 farming industry. *J Fish Dis* 32:115–118 960
- Dashtianasab A, Kakoolaki S, Sharif Rohani M, Yeganeh V (2012) In 961
 vitro effects of *Sargassum latifolium* (Agardeh, 1948) against se- 962
 lected bacterial pathogens of shrimp. *Iran J Fish Sci* 11(4):765–775 963

- 964 Dawczynski C, Schubert R, Jahreis G (2007) Amino acids, fatty acids,
965 and dietary fibre in edible seaweed products. *Food Chem* 103:891–
966 899
- 967 de Lara-Isassi G, Álvarez-Hernández S, Collado-Vides L (2000)
968 Ichthyotoxic activity of extracts from Mexican marine macroalgae.
969 *J Appl Phycol* 12:45–52
- 970 Defoirdt T, Crab R, Wood TK, Sorgeloos P, Verstraete W, Bossier P
971 (2006) Quorum sensing-disrupting brominated furanones protect the
972 gnotobiotic brine shrimp *Artemia franciscana* from pathogenic
973 *Vibrio harveyi*, *Vibrio campbellii*, and *Vibrio parahaemolyticus*
974 isolates. *Appl Environ Microbiol* 72:6419–6423
- 975 Dillehay TD, Ramírez C, Pino M, Collins MB, Rossen J, Pino-Navarro
976 JD (2008) Monte Verde: seaweed, food, medicine, and the peopling
977 of South America. *Science* 320:784–786
- 978 Dobretsov S, Teplitski M, Paul V (2009) Mini-review: quorum sensing in
979 the marine environment and its relationship to biofouling.
980 *Biofouling* 25:413–427
- 981 Dubber D, Harder T (2008) Extracts of *Ceramium rubrum*, *Mastocarpus*
982 *stellatus* and *Laminaria digitata* inhibit growth of marine and fish
983 pathogenic bacteria at ecologically realistic concentrations.
984 *Aquaculture* 274:196–200
- 985 El Gamal AA (2010) Biological importance of marine algae. *Saudi*
986 *Pharm J* 18:1–25
- 987 El Ghany NAA, Alla HMLA (2008) A trial for treatment of
988 ichthyophonosis in cultured *Oreochromis niloticus* using fucus and
989 neem plants. 8th International Symposium on Tilapia in
990 Aquaculture. Proceedings. Cairo, Egypt, 12–14 October, 2008. pp.
991 1329–1349
- 992 Food and Agriculture Organization of the United Nations (FAO) (2014)
993 Global aquaculture production. [http://www.fao.org/fishery/
994 statistics/global-aquaculture-production/en](http://www.fao.org/fishery/statistics/global-aquaculture-production/en). Accessed 14 May 2014
- 995 Ganeshamurthy R, Kumar TTA, Dhayanithi NB (2012) Effect of second-
996 ary metabolites of the seaweed (*Halimeda micronesia*) at
997 Lakshadweep islands against aquatic pathogens. *Int J Pharm Bio*
998 *Sci* 3:B213–B220
- 999 Genovese G, Faggio C, Gugliandolo C, Torre A, Spanò A, Morabito M,
1000 Maugeri TL (2012) In vitro evaluation of antibacterial activity of
1001 *Asparagopsis taxiformis* from the Straits of Messina against patho-
1002 gens relevant in aquaculture. *Mar Environ Res* 73:1–6
- 1003 Govindasamy C, Narayani S, Arulpriya M, Ruban P, Anantharaj K,
1004 Srinivasan R (2011) In vitro antimicrobial activities of seaweed
1005 extracts against human pathogens. *J Pharm Res* 4:2076–2077
- 1006 Gupta S, Abu-Ghannam N (2011a) Bioactive potential and possible
1007 health effects of edible brown seaweeds. *Trends Food Sci Tech* 22:
1008 315–326
- 1009 Gupta S, Abu-Ghannam N (2011b) Recent developments in the applica-
1010 tion of seaweeds or seaweed extracts as a means for enhancing the
1011 safety and quality of foods. *Innov Food Sci Emerg* 12:600–609
- 1012 Henry EC (2012) The use of algae in fish feeds as alternatives to fish
1013 meals. [http://users.auth.gr/kganias/Aquaculture/AQUAFEED_
1014 selection.pdf](http://users.auth.gr/kganias/Aquaculture/AQUAFEED_selection.pdf). Accessed May 14 2014
- 1015 Heuer OE, Kruse H, Grave K, Collignon P, Karunasagar I, Angulo FJ
1016 (2009) Human health consequences of use of antimicrobial agents in
1017 aquaculture. *Clin Infect Dis* 49:1248–1253
- 1018 Hierholtzer A, Chatellard L, Kierans M, Akunna JC, Collier PJ (2014)
1019 The impact and mode of action of phenolic compounds extracted
1020 from brown seaweed on mixed anaerobic microbial cultures. *J Appl*
1021 *Microbiol* 114:964–973
- 1022 Higa T, Kuniyoshi M (2000) Toxins associated with medicinal and edible
1023 seaweeds. *J Toxicol Toxin Rev* 19:119–137
- 1024 Holdt SL, Kraan S (2011) Bioactive compounds in seaweed: functional
1025 food applications and legislation. *J Appl Phycol* 23:543–597
- 1026 Huntingford FA, Adams C, Braithwaite VA, Kadri S, Pottinger TG,
1027 Sandøe P, Turnbull JF (2006) Current issues in fish welfare. *J Fish*
1028 *Biol* 68:332–372
- Hutson KS, Mata L, Paul NA, de Nys R (2012) Seaweed extracts as a
1029 natural control against the monogenean ectoparasite, *Neobenedenia*
1030 sp., infecting farmed barramundi (*Lates calcarifer*). *Int J Parasitol*
1031 42:1135–1141
- Ibañez E, Herrero M, Mendiola JA, Castro-Puyana M (2012) Extraction
1032 and characterization of bioactive compounds with health benefits
1033 from marine resources: macro and micro algae, cyanobacteria, and
1034 invertebrates. In: Hayes M (ed) *Marine bioactive compounds: sources,
1035 characterization and applications*. Springer, Berlin, pp 55–
1036 98
- Immanuel G, Vincybai VC, Sivaram V, Palavesam A, Marian MP (2004)
1037 Effect of butanolic extracts from terrestrial herbs and seaweeds on
1038 the survival, growth and pathogen (*Vibrio parahaemolyticus*) load
1039 on shrimp *Penaeus indicus* juveniles. *Aquaculture* 236:53–65
- Immanuel G, Sivagnanavelmurugan M, Balasubramanian V, Palavesam
1040 A (2010) Effect of hot water extracts of brown seaweeds *Sargassum*
1041 spp. on growth and resistance to white spot syndrome virus in
1042 shrimp *Penaeus monodon* postlarvae. *Aquac Res* 41:e545–e553
- Immanuel G, Sivagnanavelmurugan M, Balasubramanian V, Palavesam
1043 A (2012) Sodium alginate from *Sargassum wightii* retards mortal-
1044 ities in *Penaeus monodon* postlarvae challenged with white spot
1045 syndrome virus. *Dis Aquat Org* 99:187–196
- Jha B, Kavita K, Westphal J, Hartmann A, Schmitt-Kopplin P (2013)
1051 Quorum sensing inhibition by *Asparagopsis taxiformis*, a marine
1052 macro alga: separation of the compound that interrupts bacterial
1053 communication. *Mar Drugs* 11:253–265
- Jiao G, Yu G, Wang W, Zhao X, Zhang J, Ewart SH (2012) Properties of
1054 polysaccharides in several seaweeds from Atlantic Canada and their
1055 potential anti-influenza viral activities. *J Ocean Univ China* 11:205–
1056 212
- Johansen LH, Jensen I, Mikkelsen H, Bjørn PA, Jansen PA, Bergh Ø
1057 (2011) Disease interaction and pathogens exchange between wild
1058 and farmed fish populations with special reference to Norway.
1059 *Aquaculture* 315:167–186
- Kang MC, Kim KN, Kang SM, Yang X, Kim EA, Song CB, Nah JW,
1060 Jang MK, Lee JS, Jung WK, Jeon YJ (2013) Protective effect of
1061 dieckol isolated from *Ecklonia cava* against ethanol caused damage
1062 in vitro and in zebra fish model. *Environ Toxicol Pharmacol* 36:
1063 1217–1226
- Kanjana K, Radtanatip T, Asuvapongpatana S, Withyachumnarnkul B,
1064 Wongprasert K (2011) Solvent extracts of the red seaweed
1065 *Gracilaria fisheri* prevent *Vibrio harveyi* infections in the black tiger
1066 shrimp *Penaeus monodon*. *Fish Shellfish Immunol* 30:389–396
- Karthikaidevi G, Manivannan K, Thirumaran G, Anantharaman P,
1067 Balasubramanian T (2009) Antibacterial properties of selected
1068 green seaweeds from Vedalai coastal waters; Gulf of Mannar marine
1069 biosphere reserve. *Glob J Pharmacol* 3:107–112
- Kibenge FSB, Godoy MG, Fast M, Workenhe S, Kibenge MJT (2012)
1070 Countermeasures against viral diseases of farmed fish. *Antivir Res*
1071 95:257–281
- Kim SY, Kim SR, Oh MJ, Jung SJ, Kang SY (2011) In vitro antiviral
1072 activity of red alga, *Polysiphonia morrowii* extract and its
1073 bromophenols against fish pathogenic infectious hematopoietic necro-
1074 sis virus and infectious pancreatic necrosis virus. *J Microbiol* 49:
1075 102–106
- Lu K, Lin W, Liu J (2008) The characteristics of nutrient removal and
1076 inhibitory effect of *Ulva clathrata* on *Vibrio anguillarum* 65. *J Appl*
1077 *Phycol* 20:1061–1068
- Maheswaran ML, Padmavathy S, Gunalan B (2013) Screening and
1078 characterization of marine seaweeds and its antimicrobial potential
1079 against fish pathogens. *Int J Fish Aquat Stud* 1:1–13
- Manefield M, Harris L, Rice SA, de Nys R, Kjelleberg S (2000)
1080 Inhibition of luminescence and virulence in the black tiger prawn
1081 (*Penaeus monodon*) pathogen *Vibrio harveyi* by intercellular signal
1082 antagonists. *Appl Environ Microbiol* 66:2079–2084

- 1094 Manefield M, Welch M, Givskov M, Salmond GPC, Kjelleberg S (2001)
1095 Halogenated furanones from the red alga, *Delisea pulchra*, inhibit
1096 carbapenem antibiotic synthesis and exoenzyme virulence factor
1097 production in the phytopathogen *Erwinia carotovora*. FEMS
1098 Microbiol Lett 205:131–138
- 1099 Manilal A, Sujith S, Selvin J, Seghal Kiran G, Shakir C (2009) In vivo
1100 antiviral activity of polysaccharide from the Indian green alga,
1101 *Acrosiphonia orientalis* (J. Agardh): potential implication in shrimp
1102 disease management. World J Fish Mar Sci 1:278–282
- 1103 Manilal A, Selvin J, George S (2012) In vivo therapeutic potentiality of
1104 red seaweed, *Asparagopsis* (Bonnemaisoniales, Rhodophyta) in the
1105 treatment of vibriosis in *Penaeus monodon* Fabricius. Saudi J Biol
1106 Sci 19:165–175
- 1107 Martinez JL (2009) The role of natural environments in the evolution of
1108 resistance traits in pathogenic bacteria. Proc R Soc B 276:2521–
1109 2530
- 1110 Marudhupandi T, Kumar TTA (2013) Antibacterial effect of fucoidan
1111 from *Sargassum wightii* against the chosen human bacterial patho-
1112 gens. Int Curr Pharm J 2:156–158
- 1113 Mata L, Wright E, Owens L, Paul N, de Nys R (2013) Water-soluble
1114 natural products from seaweed have limited potential in controlling
1115 bacterial pathogens in fish aquaculture. J Appl Phycol 25:1963–
1116 1973
- 1117 McLoughlin M (2006) Fish vaccination—a brief overview. [http://www.
1118 imb.ie/images/uploaded/documents/Fish%20Vaccine%
1119 20Overview.pdf](http://www.imb.ie/images/uploaded/documents/Fish%20Vaccine%20Overview.pdf). Accessed 14 May 2014
- 1120 Miranda CD, Zemelman R (2002) Bacterial resistance to oxytetracycline
1121 in Chilean salmon farming. Aquaculture 212:31–47
- 1122 Mohamed S, Hashim SN, Rahman HA (2012) Seaweeds: a sustainable
1123 functional food for complementary and alternative therapy. Trends
1124 Food Sci Technol 23:83–96
- 1125 Moo-Puc R, Robledo D, Freile-Pelegrin Y (2008) Evaluation of selected
1126 tropical seaweeds for in vitro anti-trichomonad activity. J
1127 Ethnopharmacol 120:92–97
- 1128 Omar HH, Gumgumji NM, Shiek HM, El Kazan MM, El Gendy AM
1129 (2012) Inhibition of the development of pathogenic fungi by extracts
1130 of some marine algae from the Red Sea of Jeddah, Saudi Arabia. Afr
1131 J Biotechnol 11:13697–13704
- 1132 Osman MEH, Abu-Shady AM, Elshobary ME (2012) The seasonal
1133 fluctuation of the antimicrobial activity of some macroalgae collect-
1134 ed from Alexandria Coast, Egypt. In: Annous BA, Gurtler JB (eds)
1135 *Salmonella*: distribution, adaptation, control measures and molecu-
1136 lar technologies, InTech, pp 173–186
- 1137 Patel S (2012) Therapeutic importance of sulfated polysaccharides from
1138 seaweeds: updating the recent findings. 3 Biotechnol 2:171–185
- 1139 Pereira RC, Costa-Lotufo LV (2012) Bioprospecting for bioactives from
1140 seaweeds: potential, obstacles and alternatives. Rev Bras Farmacogn
1141 Braz J Pharmacogn 22:894–905
- 1142 Petersen A, Andersen JS, Kaewmak T, Somsiri T, Dalsgaard A (2002)
1143 Impact of integrated fish farming on antimicrobial resistance in a
1144 pond environment. Appl Environ Microbiol 68:6036–6042
- 1145 Plaza M, Cifuentes A, Ibáñez E (2008) In the search of new functional
1146 food ingredients from algae. Trends Food Sci Technol 19:31–39
- 1147 Plaza M, Santoyo S, Jaime L, García-Blairsy Reina G, Herrero M,
1148 Señoráns FJ, Ibáñez E (2010) Screening for bioactive compounds
1149 from algae. J Pharm Biomed Anal 51:450–455
- 1150 Radhika D, Veerabahu C, Priya R, Mohaideen A (2014) A comparative
1151 study of biopotential of crude and fractionated extracts of some sea
1152 weeds from Tuticorin coast. Int J Phytopharmacol 5:27–30
- 1153 Rasch M, Buch C, Austin B, Slierendrecht WJ, Ekmann KS, Larsen JL,
1154 Johansen C, Riedel K, Eberl L, Givskov M, Gram L (2004) An
1155 inhibitor of bacterial quorum sensing reduces mortalities caused by
1156 vibriosis in rainbow trout (*Oncorhynchus mykiss*, Walbaum). Syst
1157 Appl Microbiol 27:350–359
- Rebecca LJ, Dhanalakshmi V, Sharmila S (2012) Effect of the extract of
Ulva sp on pathogenic microorganisms. J Chem Pharm Res 4:4875–
4878
- Romero J, Feijóo CG, Navarrete P (2012) Antibiotics in Aquaculture –
Use, Abuse and Alternatives. In: Carvalho ED, David GS, Silva RJ
(eds) Health and environment in aquaculture. InTech, Croatia, pp
159–198
- Rudtanatip T, Asuvapongpatana S, Withyachumnarnkul B, Wongprasert
K (2014) Sulfated galactans isolated from the red seaweed
Gracilaria fisheri targeted the envelope proteins of white spot
syndrome virus and protected against viral infection in shrimp
haemocytes. J Gen Virol. doi:10.1099/vir.0.062919-0
- Rutherford ST, Bassler BL (2014) Bacterial quorum sensing: its role in
virulence and possibilities for its control. Cold Spring Harb Perspect
Med 2:a012427
- Saha S, Navid MH, Bandyopadhyay SS, Schnitzler P, Ray B (2012)
Sulfated polysaccharides from *Laminaria angustata*: structural fea-
tures and in vitro antiviral activities. Carbohydr Polym 87:123–130
- Salvador N, Garreta AG, Lavelli L, Ribera MA (2007) Antimicrobial
activity of Iberian macroalgae. Sci Mar 71:101–113
- Saritha K, Mani AE, Priyalaxmi M, Patterson J (2013) Antibacterial
activity and biochemical constituents of seaweed *Ulva lactuca*.
Glob J Pharmacol 7:276–282
- Selvin J, Manilal A, Sujith S, Kiran GS, Lipton AP (2011) Efficacy of
marine green alga *Ulva fasciata* extract on the management of
shrimp bacterial diseases. Lat Am J Aquat Res 39:197–204
- Silva GC, Albuquerque-Costa R, Oliveira-Peixoto JR, Pessoa-
Nascimento FE, de Macedo-Carneiro PB, dos Fernandes-Vieira
RHS (2013) Tropical Atlantic marine macroalgae with bioactivity
against virulent and antibiotic resistant *Vibrio*. Lat Am J Aquat Res
41:183–188
- Singh M, Manikandan S, Kumaraguru AK (2012) In vitro antibacterial
activity of selected brown marine macroalgae extracts collected
from the Pudumadam Coast of “Gulf of Mannar” region against
fish pathogens. Int J Human Genet Med Biotechnol Microbiol Stud.
ISSN (Online) 2319–1732
- Sirirustananun N, Chen JC, Lin YC, Yeh ST, Liou CH, Chen LL, Sim SS,
Chiew SL (2011) Dietary administration of a *Gracilaria*
tenuistipitata extract enhances the immune response and resistance
against *Vibrio alginolyticus* and white spot syndrome virus in the
white shrimp *Litopenaeus vannamei*. Fish Shellfish Immunol 31:
848–855
- Sivagnanavelmurugan M, Marudhupandi T, Palavesam A, Immanuel G
(2012) Antiviral effect of fucoidan extracted from the brown sea-
weed, *Sargassum wightii*, on shrimp *Penaeus monodon* postlarvae
against White Spot Syndrome Virus. J World Aquacult Soc 43:697–
706
- Sivakumar K, Kannappan S, Dineshkumar M, Patil PK (2014)
Evaluation of marine macro alga, *Ulva fasciata* against bio-
luminescent causing *Vibrio harveyi* during *Penaeus monodon*
larviculture. Afr J Microbiol Res 8:803–813
- Smit AJ (2004) Medicinal and pharmaceutical uses of seaweed natural
products: a review. J Appl Phycol 16:245–262
- Son M, Lee M, Sung GH, Lee T, Shin YS, Cho H, Lieberman PM, Kang
H (2013) Bioactive activities of natural products against Herpesvirus
infection. J Microbiol 51:545–551
- Stern J, Hagerman A, Steinberg P, Magon P (1996) Phlorotannin–protein
interactions. J Chem Ecol 22:1877–1899
- Sudheer NS, Philip R, Singh ISB (2012) Anti-white spot syndrome virus
activity of *Ceriops tagal* aqueous extract in giant tiger shrimp
Penaeus monodon. Arch Virol 157:1665–1675
- Takahashi Y, Uehara K, Watanabe R, Okumura T, Yamashita T, Omura H,
Yomo T, Kawano T, Kanemitsu A, Narasaka H, Suzuki N, Itami T
(1998) Efficacy of oral administration of fucoidan, a sulfated poly-
saccharide, in controlling white spot syndrome in kuruma shrimp in
Japan. In: Flegel TW (ed) Advances in shrimp biotechnology.

- 1224 National Center for Genetic Engineering and Biotechnology, 1244
 1225 Bangkok, pp 171–173 1245
- 1226 Thanigaivel S, Vijayakumar S, Mukherjee A, Chandrasekaran N, Thomas 1246
 1227 J (2014) Antioxidant and antibacterial activity of *Chaetomorpha* 1247
 1228 *antennina* against shrimp pathogen *Vibrio parahaemolyticus*. 1248
 1229 *Aquaculture* 433:467–475 1249
- 1230 The Fish Site (2010) Aquatic animal diseases and their economic impact. 1250
 1231 [http://www.thefishsite.com/articles/896/aquatic-animal-diseases-](http://www.thefishsite.com/articles/896/aquatic-animal-diseases-and-their-economic-impact#sthash.CrjIsPk9.dpuf) 1251
 1232 [and-their-economic-impact#sthash.CrjIsPk9.dpuf](http://www.thefishsite.com/articles/896/aquatic-animal-diseases-and-their-economic-impact#sthash.CrjIsPk9.dpuf). Accessed 11 1252
 1233 March 2014 1253
- 1234 Traifalgar RF, Serrano AE, Corre V, Kira H, Tung HT, Michael FR, Kader 1254
 1235 MA, Laining A (2009) Evaluation of dietary fucoidan supplementa- 1255
 1236 tion effects on growth performance and vibriosis resistance of 1256
 1237 *Penaeus monodon* postlarvae. *Aquac Sci* 57:167–174 1257
- 1238 Vairappan CS, Suzuki M (2000) Dynamics of total surface bacteria and 1258
 1239 bacterial species counts during desiccation in the Malaysian sea 1259
 1240 lettuce, *Ulva reticulata* (Ulvales, Chlorophyta). *Phycol Res* 48:55–61 1260
- 1241 Vairappan CS, Daitoh M, Suzuki M, Abe T, Masuda M (2001) 1261
 1242 Antibacterial halogenated metabolites from the Malaysian 1262
 1243 *Laurencia* species. *Phytochemistry* 58:291–297 1263
 1264
- Vijayabaskar P, Shiyamala V (2011) Antibacterial activities of brown 1244
 marine algae (*Sargassum wightii* and *Turbinaria ornata*) from the 1245
 Gulf of Mannar biosphere reserve. *Advan Biol Res* 5:99–102 1246
- Vonhron-Sénécheau C, Kaiser M, Devambe I, Vastel A, Mussio I, 1247
 Rusig AM (2011) Antiprotozoal activities of organic extracts from 1248
 French marine seaweeds. *Mar Drugs* 9:922–933 1249
- Wang W, Wang SX, Guan HS (2012) The antiviral activities and mech- 1250
 anisms of marine polysaccharides: an overview. *Mar Drugs* 10: 1251
 2795–2816 1252
- Wijesinghe WJ, Kim EA, Kang MC, Lee WW, Lee HS, Vairappan CS, 1253
 Jeon YJ (2014) Assessment of anti-inflammatory effect of 5- 1254
 hydroxypalisadin B isolated from red seaweed *Laurencia snackeyi* 1255
 in zebrafish embryo in vivo model. *Environ Toxicol Pharmacol* 37: 1256
 110–117 1257
- World Health Organization (2011) Tackling antibiotic resistance from a 1258
 food safety perspective in Europe. [http://www.euro.who.int/_data/](http://www.euro.who.int/_data/assets/pdf_file/0005/136454/e94889.pdf) 1259
[assets/pdf_file/0005/136454/e94889.pdf](http://www.euro.who.int/_data/assets/pdf_file/0005/136454/e94889.pdf) Accessed 16 Oct 2014 1260
- Xu N, Fan X, Yan X, Li X, Niu R, Tseng CK (2003) Antibacterial 1261
 bromophenols from the marine red alga *Rhodomela confervoides*. 1262
Phytochemistry 62:1221–1224 1263

UNCORRECTED PROOF

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES.

- Q1. Please check if the affiliations are presented correctly.
- Q2. Kindly check the modifications made in Tables 1 and 2 if appropriate.
- Q3. “Hutson et al. (2013)” is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q4. The citation “Hierholtzer et al., 2012” (original) has been changed to “Hierholtzer et al. 2014”. Please check if appropriate.
- Q5. The citation “Rutherford and Bussler 2012” (original) has been changed to “Rutherford and Bassler 2014”. Please check if appropriate.
- Q6. “Pereira et al. (2012)” is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.

UNCORRECTED PROOF